Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
Joanna Kuc, Hannes Kettner, Fernando Rosas, David Erritzoe, Eline Haijen, Mendel Kaelen, David Nutt & Robin L. Carhart-Harris
Facial Neuralgia May Be Linked to Vitamin B12 Deficiency
Neurology Reviews – November 17, 2009
Some patients with facial neuralgia respond favorably to vitamin B12 injections.
Jitendra K. Baruah, MD, and Gita R. Baruah, MD, presented a review of 17 patients (10 women; mean age, 55.4) who experienced frequent episodes of isolated unilateral facial neuralgic pain not typical of trigeminal neuralgia. A neurologic examination revealed that corneal and facial sensation, along with the strength of both facial and trigeminal nerve innervated muscles, were normal.
All patients reported a decrease in touch and pain sensation, as well as numbness on the affected side. The blink reflex and trigeminal nerve–evoked response were abnormal, and all subjects had low levels of serum B12 (average, 186.7 pg/mL; reference range, 300 to 900 pg/mL) and high levels of methylmalonic acid, indicating defective gastrointestinal absorption of vitamin B12, the researchers noted.
The patients received intramuscular or subcutaneous injections of 1,000 mcg vitamin B12, once a week for four weeks. The dose was subsequently tapered down to two-week intervals for eight weeks, and then once a month for a year, at which point patients will be re-evaluated.
Identifying and Treating Patients With Facial Neuralgia
The researchers observed the vitamin B12 deficiency during clinical evaluations of patients in their respective practices. “It was somewhat unexpected that vitamin B12 deficiency can cause isolated facial neuralgia,” Dr. Jitendra K. Baruah, a neurologist based in Milwaukee, told Neurology Reviews. “Treatment for facial neuralgia is sometimes very difficult, and patients may often go into multimodalities treatment without much success. Knowing that this condition is remediable with vitamin B12 therapy, it is important to identify these patients and treat them accordingly.”
The investigators also found that many patients with facial neuralgia also developed cold sores (herpes simplex labialis) on the site of the facial neuralgia, and the cold sores also responded to vitamin B12 treatment. “It may be possible that having cold sores means there is an active herpes simplex virus located in the gasserian ganglion, indicating that there may be some compromise of that particular side and these trigeminal nerves are found to be more susceptible to deficiencies to vitamins, such as B12,” Dr. Baruah explained.
—Rebecca K. Abma
Article from – MD Edge
The Canadian revival of psychedelic drug research
In the 1950s, the Prairies were a hub for psychedelic science. Some 60 years later, Canadian researchers are showing a renewed interest in the therapeutic use of psychedelics.
Psychiatrists in Vancouver will soon begin a phase III clinical trial of MDMA, a hallucinogenic drug commonly known as ecstasy, for patients suffering from post-traumatic stress disorder (PTSD). The treatment consists of three monthly, eight-hour sessions under the influence of MDMA, interspersed by nine 90-minute sessions without it. This work is historically significant, say the researchers involved, because it marks the first time in more than four decades that an illegal psychedelic drug has been clinically tested in Canada.
This double-blind, placebo-controlled study is being run by the British Columbia Centre on Substance Use (BCCSU), a provincial organization with a mandate to develop, evaluate and help implement evidence-based approaches to treat substance use and addiction. Vancouver is one of 16 locations in North America and Israel where teams are working on the same experiment under the guidance of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS).
A phase III clinical trial is typically the last phase of review a drug undergoes before it is approved for public use. Only 25 to 30 percent of drugs that enter phase III trials pass successfully, but MAPS’ phase II review, which concluded in 2016, produced glowing results. One year after patients were treated with MDMA, 68 percent reported that they no longer experienced symptoms.
Eliminating symptoms entirely would be a huge breakthrough, as PSTD is notoriously difficult to treat, says Mark Haden, executive director of MAPS Canada and an adjunct professor at the University of British Columbia’s School of Population and Public Health. “The traumatic memory of the incident replays like a tape loop in the patient’s mind. MDMA doesn’t eliminate the traumatic memory, but it takes away the emotional impact so that the memory no longer controls a person,” explains Dr. Haden, who hopes to have MDMA approved as a treatment for PTSD by the U.S. Food and Drug Administration and by Health Canada by 2021.
The MDMA work is just one aspect of a recent resurgence of scientific curiosity about the healing properties of psychedelic drugs, an area of investigation that initially showed considerable promise in the 1950s for the treatment of mental health problems and substance abuse, including alcoholism. Much of that pioneering research took place in Saskatchewan at the Weyburn Mental Hospital under the direction of Humphry Osmond, an English psychiatrist, and Abram Hoffer, a Canadian biochemist, who were given great freedom to follow their medical instincts by the government of then-premier Tommy Douglas.
Erika Dyck, who holds the Canada Research Chair in the History of Medicine at the University of Saskatchewan and is the author of the 2008 book Psychedelic Psychiatry: LSD from Clinic to Campus, says Drs. Osmond and Hoffer began experimenting with LSD, mescaline and peyote in order to find an alternative to the brutal methods of electroshock and lobotomy that were often used for treating mental disorders at the time. The quest became surprisingly free-ranging in scope. “Osmond and Hoffer not only treated patients with psychedelics, they also encouraged doctors, nurses and support staff to take the drugs,” says Dr. Dyck. They even had their wives partake, and Dr. Osmond convinced architect Kiyoshi Izumi to ingest LSD several times before he submitted his designs for a new mental hospital in Yorkton, Saskatchewan.
All this exploration of the human psyche came to a sudden halt in the late 1960s when politicians, reacting to the growing recreational use of LSD, peyote and psilocybin, reclassified these substances as dangerous drugs with no medical value.
Today, however, the research is gaining fresh momentum with new investigations of the powers of LSD, psilocybin (the active ingredient in magic mushrooms) and ayahuasca (a South American brew that contains a hallucinogen known as DMT). LSD is being evaluated for its ability to relieve anxiety, psilocybin for the cessation of smoking, the treatment of depression and reducing the fear of death in people with terminal illness, and ayahuasca for its ability to combat depression.
“Psychedelics, under carefully controlled conditions, can create experiences of wonder and awe and a connection to a divine realm that leads to significant behavioural changes,” says Kenneth Tupper, director of implementation and partnerships at BCCSU and, like Dr. Haden, an adjunct professor in the School of Population and Public Health at UBC.
The topic has received mainstream media exposure with the publication of books such as Michael Pollan’s 2018 bestseller, How to Change Your Mind: What the New Science of Psychedelics Teaches Us about Consciousness, Dying, Addiction, Depression, and Transcendence, the global interchange on social media and a growing dissatisfaction with conventional drug therapy.
“It’s a subject that is being increasingly addressed by a number of distinguished people and across many disciplines,” says Brian Rush, a professor in the departments of psychiatry and public health at the University of Toronto and a researcher with the Centre for Addiction and Mental Health. “I was recently invited to give a presentation at a prestigious international conference in Lisbon. The conference had a category for psychedelics. I’d never encountered that before.”
Psychedelics are a class of drugs that affect the brain’s serotonin receptors, triggering a variety of changes in sight, hearing and thought and producing an altered state of consciousness. Drugs commonly included in this category are LSD (acid), psilocybin (magic mushrooms), MDMA (ecstasy) and DMT (dimethyltryptamine). The term “psychedelics” for these substances was coined by psychiatrist Humphry Osmond during a 1956 exchange of letters with writer Aldous Huxley. Dr. Osmond wrote: “To fathom Hell or soar angelic/Just take a pinch of psychedelic.”
But while there is clear evidence of renewed interest in psychedelic drugs, exactly how these compounds affect the biology of the brain is still something of a mystery. The emerging view among neuroscientists is that psychedelics dissolve the barriers in the brain that separate the networks that perform such common functions as vision, movement and hearing. As a result, crosstalk ensues between circuits that normally do not interact. The temporary formation of a more integrated brain may spark the spiritual feelings of “connectedness” often reported by users of these drugs.
While this work is going on, Canadian scientists are exploring other frontiers of the psychedelic spectrum. Adèle Lafrance Robinson, a consulting psychologist and associate professor of psychology at Laurentian University, published a 2017 study that found that ayahuasca may have potential as a therapy for difficult-to-treat eating disorders. Dr. Robinson’s data was gathered by interviewing 16 individuals with a diagnosed eating disorder who had also participated in ayahuasca ceremonies.
Microdosing: the next frontier
Another researcher, Thomas Anderson, a PhD student and cognitive neuroscientist at U of T, has zeroed in on the phenomenon of microdosing, an emerging trend in which people take about one-tenth the dose of LSD or psilocybin typically consumed for recreational use. Because the dose is so low, individuals reportedly experience only subtle changes and can go about their regular day without running the risk of hallucinations. Although there is no established factual evidence that microdosing yields any beneficial effects, many users are convinced that it works like a mega-vitamin pill for the brain, sharpening creativity and cognition, and improving mood.
In 2017, Mr. Anderson and Rotem Petranker, a graduate student of psychology at York University, conducted one of the first scientific investigations of microdosing. Through an anonymous online survey, they queried 909 participants ranging in age from late teens to late 70s from 29 countries about the quantity and frequency of their psychedelic use, their reasons for microdosing, the effect on mood, focus and creativity, and the benefits and drawbacks. The study found that microdosers scored higher on measures of wisdom, open-mindedness and creativity, and lower on neurotic and dysfunctional attitudes.
A few people reported increased anxiety while microdosing, but the most common drawback cited was the illegal status of these drugs, which compels users to obtain them on the black market. “People reported having a hard time finding their dosage or having to deal with drug dealers and being anxious about how they’re partaking in an illegal activity,” says Mr. Petranker.
Meanwhile, back in Vancouver, Dr. Tupper says that the BCCSU is preparing for its second foray into psychedelics: the use of psilocybin for the treatment of substance-use disorders. But this type of research still faces serious obstacles. The MMDA project took six years and $200,000 simply to get in motion, and the phase III trial is expected to cost about $26 million.
“Funding is a constant headache because we don’t have support from the pharmaceutical industry,” says Dr. Haden. Instead, MAPS’ funding comes from private donors, many of them connected with the tech sector. As Dr. Haden notes, because the therapy and cure for PSTD involves so few doses of MDMA, it doesn’t suit the business model of Big Pharma. “The drug companies want drugs that people have to take on a daily basis, to treat symptoms, not the problem.”
Should this avenue of research continue to produce positive results, however, we may be on the brink of a revolution in mental health care. As the influential Czech psychiatrist Stanislav Grof once stated: “It does not seem to be an exaggeration to say that psychedelics, used responsibly and with proper caution, may become for psychiatry what the microscope is for biology or the telescope is for astronomy.”
Story from University Affairs
Penn State research shows medical marijuana may stop cancer cell growth
By Michelle Drapac –
New research from Penn State College of Medicine shows medical marijuana may stop the growth of colon cancer cells.
According to the National Cancer Institute, colorectal cancer is one of the most common cancers diagnosed in the U.S. The research looks to change the outcome for patients.
“Colorectal cancer is the third most common cause of cancer in the United States and it’s also the third most common cause of cancer-related deaths in the U.S.,” said Wesley Raup-Konsavage, the research project manager.
The researchers looked at synthetic derivatives of the compounds found in medical marijuana and how they interacted with cancer cells in test tubes.
“Of the 370 compounds, it turns out that 10 were fairly effective against all colon cancer cell lines,” said Kent Vrana, chair of the Department of Pharmacology at Penn State College of Medicine.
Researchers will next look at making these compounds more potent and effective against cancer cells.
“The possibility for medical marijuana is immediate because that can be used now in the Commonwealth of Pennsylvania,” said Vrana. “We just don’t know what it’s doing. In terms of these specialized chemicals, they probably wouldn’t become true drugs for another five to 10 years.”
While this research was focused mainly on colon cancer cells, it could impact other cancer cells as well.
“We have a sense for what works there. We suspect it will work for other things,” said Vrana. “We’re actually trying it for neuroblastoma right now.”
The National Institutes of Health helped support the study, which took about a year and a half. Right now in Pennsylvania, there are about 20 qualifying conditions to become a medical marijuana patient, which include cancer, autism, epilepsy, and HIV.
Story from WKBN News
Psilocybin, the Active Ingredient in ‘Magic Mushrooms,’ Could Treat Depression: Study
DECEMBER 14, 2019, By CNN WIRE
“Magic mushrooms” may have moved one step closer to becoming a treatment for depression.…
The study, conducted by King’s College London and mental healthcare company Compass Pathways, administered psilocybin to 89 healthy adult volunteers.
The study compared the effects of 10mg and 25mg doses of psilocybin, and a placebo.
There were “no serious adverse events” and “no negative effects” on cognitive and emotional function among the volunteers that took psilocybin, according to a Compass Pathways press release. Instead, the volunteers experienced “changes in sensory perception and positive mood alteration” — typical effects of psychedelic drugs.
“The results of the study are clinically reassuring and support further development of psilocybin as a treatment for patients with mental health problems that haven’t improved with conventional therapy, such as treatment resistant depression,” said James Rucker, one of the lead researchers from King’s College London, in the press release.
This is just the first of two phases in their testing — the second phase trial will involve over 200 patients with depression across Europe and North America.
More than 264 million people worldwide are affected by depression, according to the World Health Organization. The most common pharmaceutical treatment is to take antidepressants like Prozac, which increase levels of serotonin in the brain to improve mood.
But this type of antidepressant doesn’t work for everyone, and is generally prescribed as a long-term treatment to maintain effectiveness.
By contrast, psychedelic drugs quickly alter our brain function, and could therefore potentially treat patients in just a few doses when combined with therapy, researchers have suggested. Though research remains in the early stages, such a treatment could target a range of mental health conditions, including anxiety, addiction, and obsessive compulsive disorder (OCD).
Here’s how it works: theoretically, psilocybin helps “loosen” the deeply-rooted patterns of thinking and behavior behind many of these mental disorders, according to King’s College London. It could “relax” the parts of our brain that control these behaviors, thus allowing old patterns to change or fade. Patients who have received psilocybin have described coming down from the high with “new insights” and changed perspectives on their difficulties, said the university.
A 2014 Imperial College London study supports this theory. After volunteers were injected with psilocybin, the parts of their brain associated with emotional thinking became more active, while the introspective, self-conscious part of their brain became less active.
But psilocybin and other pschedelics are likely still a long way to being approved, developed, and rolled out as treatments. Only recently have US cities like Denver and Oakland moved to decriminalize psilocybin; nationwide, it’s still listed as a Schedule 1 controlled substance, meaning it has no medicinal properties under official US federal policy.
Story from KTLA
Why Doctors Are Turning to Psychedelics to Treat Depression and Addiction
Men’s Journal – by Julia Savacool- December, 2019
FOR DECADES, mental health experts have amassed anecdotal evidence that psychedelics could help people with intractable diseases like addictionOpens in a new Window., depressionOpens in a new Window., and PTSDOpens in a new Window.. Scientists at the Johns Hopkins Center for Psychedelic and Consciousness ResearchOpens in a new Window. in Baltimore, which opened in the fall, plan to test these drugs rigorously so that one day they could be prescribed. We talked with two of the center’s founding members, Alan Davis and Albert Garcia-Romeu, who are seeking out mental health and addiction treatments, to find out more about their research and how they plan to change our lives.
MJ: A lot of your focus is on psilocybin—the psychedelic agent in magic mushrooms. How does it help people suffering from depression or addiction?
DAVIS: There are a couple of ways we believe it works. First is the experience itself. People who take psilocybin report having a deeply positive, mystical experience that seems to help them alter their perspective on their situation. More specifically, people with depression tend to feel isolated and disconnected from their daily lives. The experience of taking psilocybin makes them feel an intense interconnection that stays with them after the experience is over. People also report gaining insight on their depression, like they suddenly have an awareness of what they want to change in their life to help them move forward. That awareness, coupled with this mystical-like experience, serves as the catalyst for change.
ALBERT GARCIA-ROMEU: It helps people change their perspective, which is really useful for someone who is depressed or dealing with addiction. On the physical side, psilocybin disrupts patterns in the brain—patterns of negative thinking that become entrenched over time.
How does it do that?
GARCIA-ROMEU: In a nutshell, psilocybin and other psychedelics like LSDOpens in a new Window. bind to serotonin 2A receptors, creating mood-altering effects and changes in brain function. We know psilocybin decreases amygdala blood flow in people with depression, which is associated with better antidepressantOpens in a new Window. effects. This is important because depressive symptoms seem to be associated with over-reactivity in the amygdala. Keep in mind that the data for psilocybin brain mechanisms in depression is very limited, from fewer than 20 people total. We are only starting to scratch the surface of how this works.
When people hear psychedelics, they picture mushrooms growing in the back of their college roommate’s closet—not the stuff of scientific rigor.
GARCIA-ROMEU: Honestly, it’s closer to a dorm room than a science lab. Our study setting looks like a therapist’s office: sofa, chairs, soft lighting. The most clinical item is a blood pressure monitor, which we use to keep track of physiological measures at 30- to 60-minute intervals throughout the sessions. One of the strongest predictors of a challenging experience or “bad trip” can be an overly cold and clinical setting, so we do our best to make it a place that feels warm and safe. Volunteers usually spend around eight hours here before any drug is administered, with the two people who monitor them after they’ve taken the drug.
“ONE MISCONCEPTION AROUND THIS WORK: THIS IS NOT A TAKE-TWO-AND-CALL-ME-IN-THE-MORNING TYPE OF TREATMENT.”
Where do you get the drugs?
DAVIS: The psilocybin is made for us by an academic chemist and put into a capsule that’s taken orally. This isn’t microdosingOpens in a new Window.. A dose is moderate to high—more than recreational doses in a festival environment, for example.
How are the results looking?
DAVIS: We just wrapped up the main portion of the depression study, and now we’re doing follow-ups and preparing the data for publication. We had 24 participants—all studies here are done on people, not animals. Preliminary findings show approximately half of the participants had complete remission of depression at one month after the intervention of psilocybin plus psychotherapy, which is very promising.
When will potential treatments be available to the public?
DAVIS: We expect the full study to be published this coming year. After that, it can take several years before the treatments are approved by the FDA and made available to the public.
What has been the biggest challenge you’ve encountered in your research?
DAVIS: Funding. The government hasn’t been backing this kind of work. So to get $17 million in private money [donors include entrepreneur Tim Ferriss, WordPress co-founder Matt Mullenweg, and the Steven & Alexandra Cohen Foundation]—that goes a long way to getting the quality of studies we need to move the therapeutic research forward.
A psychedelic experience lasts a few hours, but depression can haunt a person for years. How can a single dose of psilocybin have such a lasting effect?
DAVIS: A couple of days after use, the person experiences a halo effect. Their mood improves, and they may be more open to suggestion. We use that time to help them make lifestyle changes to alter their outlook. It’s not like the person just takes psilocybin, and that’s it. We still use a full therapyOpens in a new Window. approach, and we’re optimistic this may lead to greatly improved outcomes in people who have not found success in traditional treatment in the past.
So it’s 10 years from now, and psilocybin has been approved for medical use. How will it work, practically speaking? Will a person get a prescription for psilocybin?
GARCIA-ROMEU: That is probably one of the greatest misconceptions around this work. This is not a take-two-and-call-me-in-the-morning type of treatment. Nor is this like cannabis dispensaries where patients pick up the medication and take it at home, unsupervised. Psychedelics have the potential for much more intense and unpredictable psychoactive effects, so it’s best to administer them under carefully controlled conditions, in conjunction with intensive psychological support. Probably the best parallel in current medical care would be getting general anesthesia before surgery—this only happens at a medical facility under the careful supervision of a specially trained doctor and support staff.
Even so, this sounds life-changing for some people.
DAVIS: Absolutely. We see a future where we can actually heal these problems instead of simply trying to reduce symptoms. Our results point to a potential neurological and psychological basis from which we can understand this healing potential, and that could revolutionize our understanding of what “treatment” actually means. No longer would we be trying to help people get by, but they might actually heal and then thrive.
Story from Men’s Journal
Health Canada says it hasn’t tested health effects of cannabis vaping but will release new products anyway
‘There has been no analysis done,’ agency says, because products not yet on market
The federal government will allow the sale of cannabis vaping products starting next week despite not having tested the health effects of inhaling substances emitted from such devices. At least one cannabis company has preemptively pulled its product over health and safety concerns, CBC News has learned.
Cannabis vapes are among a series of new products — including edibles, extracts and topicals such as lotions — that can be legally sold in Canada as of Tuesday.
Health Canada says that while it has tested the ingredients in cannabis vaping liquids, tests on the vapour emitted when those compounds are heated have not yet been done.
“No legal products are on the market as of today,” Eric Morrissette, a spokesperson for the health agency said in an emailed statement Thursday. “So, there has been no analysis done.”
Products released in midst of vaping illness outbreak
The release of the products comes amid an outbreak of vaping-associated lung illnesses across North America involving cannabis vapes and nicotine e-cigarettes.
“In the middle of an epidemic in the United States, they still somehow come to the conclusion that there’s nothing to worry about here and we can go ahead and sell cannabis vaping products,” said Dr. Matthew Stanbrook, a respirologist at Toronto Western Hospital and deputy editor of the Canadian Medical Association Journal.
“It just really speaks to a complete lack of attention to providing any safeguards here.”
There have been 14 cases of vaping-associated lung illness reported to the Public Health Agency of Canada as of Tuesday. Three occurred in British Columbia, two in New Brunswick, four in Ontario, and five in Quebec.
“It’s sort of like the worst time that you could release these products in Canada,” said Dr. Mangala Narasimhan, the regional director of critical care medicine at Northwell Health in New York City, who has treated close to 40 cases of the illness.
“It’s crazy to me that they’re allowing this to continue and that they’re actually going to introduce it in Canada, knowing everything that we know.”
The majority of the cases of vaping illness are linked to illicit cannabis vapes. The CDC has not singled out any one brand but recommends that people not use the devices at all.
“If the leading authority in the world is making that statement, then who am I or others to challenge them?” said David Hammond, a professor of public health at the University of Waterloo who researches vaping.
“And I would suggest that the actions in Quebec, Newfoundland and Nova Scotia are more in line with that. They are still trying to figure out what is killing people and putting people in hospital.”
Health Canada said in a statement that there is a vast illegal market for cannabis vaping products in Canada and that providing legal access to regulated cannabis products “is one of the best ways to protect Canadians from the risks posed by products from the illegal market.”
The health agency said it is in close contact with the CDC and the U.S. Food and Drug Administration “to better understand their investigations into the cause or causes of the illnesses.”
Read CBC’s special coverage on vaping:
Cannabis company holding back on releasing vapes
HEXO, a Canadian cannabis company that made headlines after it announced in October it would sell cannabis for $4.49 a gram, says it will not release cannabis vapes next week as planned because of concerns over the safety of the products.
“We understand that diluting agents found in some cannabis extracts are under increased scrutiny for having potential negative health impacts,” Isabelle Robillard, HEXO’s vice-president of communications, said in a statement.
“As such, to produce quality vapes, and out of an abundance of caution, HEXO will not develop products that use these.”
Health Canada says the liquids are considered safe in many consumer products such as cosmetics and sweeteners but that “the long-term safety of inhaling the substances in vaping products is unknown and continues to be assessed.”
Robillard said HEXO is working with a research organization to further study the safety of the products and the occurrence of adverse events with cannabis vapes.
What’s allowed in cannabis vapes?
Under federal regulations, cannabis vapes cannot contain anything that may cause injury to the health of the user or anything other than “carrier substances, flavouring agents, and substances that are necessary to maintain the quality or stability of the product.”
Similar to the rules for nicotine e-cigarettes, banned ingredients for cannabis vape oils include added vitamins or minerals, nicotine or alcohol, caffeine and added sugars, sweeteners or colours.
That includes vitamin E acetate, which has been identified as a “chemical of concern” by the CDC in the vaping-related illness outbreak across North America but has not officially been confirmed as the culprit.
Health Canada will allow cannabis vaping products to contain up to 1,000 mg of THC, the main psychoactive ingredient in marijuana, per package (a gram of dry cannabis has about 100 mg of THC).
It will also allow flavours, the use of which has been discouraged by the Canadian Paediatric Society in nicotine-based vaping products because of a fear that they will make the products more attractive to young users.
“There’s no question that flavours play an important role in the appeal of vaping products to youth,” said Hammond.
“If you start adding flavours to THC vape oils or other cannabis products, it’s probably going to increase their appeal to non-users and young people. That is just common sense.”
Flavouring chemicals such as diacetyl (found in buttery flavours) are also associated with conditions such as “popcorn lung,” and pulegone (found in menthol) can have toxic effects when vaped at high levels.
Flavouring compound raises concern
One way to flavour cannabis vaping oils is to use a class of organic compounds found naturally in cannabis called terpenes.
Terpenes, which Canadian cannabis companies such as Canopy Growth, Aphria, Aurora and Organigram have confirmed to CBC News they are using in their vaping extracts, are oils that gives cannabis strains their distinct smell and taste.
But when cannabis is distilled into a vaping extract, the terpenes are removed, leaving an oil that is essentially odourless.
When those terpenes are added back into cannabis vaping liquids as flavouring, they have the potential to produce toxic emissions when vaporized, including known carcinogens such as benzene, according to a new lab study published in the journal ACS Omega.
“The big take-home message as far as the terpenes go is that people shouldn’t add a large percentage of them to the formulations,” said Dr. Robert Strongin, lead author and professor of organic chemistry at Portland State University in Oregon.
“We just don’t know the full toxic toxicity.”
“This will allow us to see if our compounds are degraded into potentially toxic products when atomized,” she said.
“Once we are confident in the safety of our vapes and formulations, we will launch our products and conduct additional post-marketing studies.”
Uncertainty over health effects
Health Canada says on its website that “relatively little is known about the pharmacological actions” of terpenes, but it has not restricted their use in the cannabis products that go on sale next week.
The agency said in a statement to CBC News that it has received 48 applications from licenced cannabis producers to sell cannabis vapes in addition to 746 applications for cartridge-based vaping systems.
It’s unclear how many will be available on the market, because that number includes instances where the same product is sold by two separate licence holders, as well as products that are essentially the same but contain different concentrations of THC.
“The only thing we can say right now with certainty is that we really just don’t have a good understanding about what the health effects are of these products,” said Dr. Constance Mackenzie, a respirologist and toxicologist at St. Joseph’s Health Care in London, Ont.
“It took decades to understand what the risks of smoking cigarettes were on the lungs. We probably shouldn’t be making the same mistakes again.”
Coverage on Vaping from CBC
Addiction Treatment Gets Psychedelic With ‘Shark Tank’ Investor-Approved Startup
We all know the lore of LSD microdosing in Silicon Valley. It’s been hailed as a job-enhancer in the tech industry. A very small dosage, around 10-15 micrograms, has been noted to lift energy and creativity—without the “trippy” effects. Let’s just say it really helps your focus.
Needless to point out, there’s so many mysteries to unlock about psychedelic drugs. This is due to the incredibly little scientific research that has been done on the topic since psychedelic, such as LSD and mushrooms, have been classified as Schedule 1 drugs.
We don’t know, over a long period of time, if microdosing actually has true positive or negative benefits, largely because of how hard it is to get funding for research.
A big reason why psychedelic drug research got side-railed in the ’60s was primarily because it became intertwined with the hippie movement. Unless, of course, it was the CIA doing top secret LSD “mind-control” experiments under the code name: MK-Ultra.
Acid guru Timothy Leary, whose mantra was “tune in, drop out,” became a target of the establishment and the man. During that era, LSD was seen as the horrific drug that crazed hippies dropped right before they committed the Manson murders. That pretty much nixed all medical research into the potential benefits of psychedelics. In fact, public schools at the time were shown “educational” films, in which those who dropped acid would surely encounter the screams of talking hot dogs.
Smash cut to 2019: Hallucinogenic drugs are now seen as a potential cure for depression, alcoholism and a means to get people off opioids.
Thus, startup company, MindMed, is getting some (get ready for a pun) buzz.
And there are no screaming hotdogs here; MindMed’s mission statement is to discover and develop medicines based on psychedelics. The company’s main priority is “to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic compound ibogaine.”
“There’s a lot of untapped value in psychedelic substances because they’re [illegal],” JR Rahn, founder of the Toronto-based startup, told The Globe and Mail.
The company is less than a year old. And already investors are listening. MindMed announced in November that it had raised $15 million in pre-public financing from Canaccord Genuity, an investment bank which was heavily involved in financing the Canadian cannabis sector. Shark Tank investor Kevin O’Leary was also part of an investment round of $6.2 million. Yes, something must be up—if MindMed got one of TV’s longest standing “sharks” to invest in the venture.
O’Leary explained to Fast Company: “This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”
The compound, 18-MC (which is based on the natural psychedelic substance ibogaine), has yet to undergo human efficacy trials, but it’s been trumpeted as potentially reducing a person’s addiction to cocaine, methamphetamine, morphine, alcohol, and, not to mention, sugar.
MindMed came about while Rahn was living in San Francisco, working for Uber, where he found inspiration from the Silicon Valley microdosing trend; not only were tech workers using it to get a focused edge, but they were also implementing usage to wean themselves off of stimulants, such as Adderall. His mission, then, became to focus on psychedelics as medicine—that wasn’t based on tripping.
“We feel psychedelics are moving into a high value creation period that is starting to attract institutional investors and not just retail investors,” Rahn said. “You can point out the studies to regulators and say ‘this works.’ That’s a defensible business,” he added, pointing out the wealth of psychedelics-related clinical trials.
MindMed’s endgame is to have patients suffering from addiction be able to pick up these medicines from their local pharmacy with a prescription.
Rahn feels that if MindMed can prove its ability to produce results with these drugs, the laws will change and allow them to push forward.
It’s good to see that research on the beneficial effects of hallucinogens has evolved beyond the scare tactics of the ’60s.
“We feel there is an immense opportunity to create next-gen versions of psychedelics for approval as FDA drugs,” said Rahn. “We believe that hallucinogenic therapies have great merit and benefits for treating addiction.”
Three quarters of teens who vape report using nicotine, marijuana, or multiple substances
A new study in the American Journal of Preventive Medicine provides data that highlight disturbing trends in teen e-cigarette use
Ann Arbor, December 16, 2019 – More teens who vape are using addictive or mind-altering substances than previously believed, according to a new study in the American Journal of Preventive Medicine, published by Elsevier. The data paint a different picture than previous research because of the significantly higher proportion (75 percent) of teens who vape using nicotine, marijuana, or multiple substances and not just flavoring. These findings add to growing public health concerns about youth vaping.
“Our study provided a more nuanced view of youth e-cigarette use behaviors than earlier studies. We found that youth were more likely to report vaping nicotine and marijuana than ‘just flavoring’ only, and that cigarette smoking intensity was associated with an increasing proportion of students reporting vaping nicotine only,” explained co-investigator Hongying Dai, PhD, Associate Professor, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
This study examined patterns of youth vaping nicotine, marijuana, and just flavoring in the past 30 days by analyzing data from the 2017 Monitoring the Future (MTF) cross-sectional study. Of the 14,560 teens participating in that study, 12 percent reported vaping within the prior 30 days, with 7.4 percent using nicotine and 3.6 percent, marijuana. Of that group, only 24.9 percent reported vaping just flavoring only, while a majority (75.1 percent) reported vaping nicotine, marijuana, or multiple substances.
Current cigarette smoking intensity was associated with an increased risk of reporting vaping all three substances. Compared with 8th graders, more 10th and 12th graders reported vaping nicotine, marijuana, and just flavoring during the study period. Female students were also less likely to report vaping these three substances than male students. Fewer non-Hispanic blacks reported vaping nicotine and just flavoring than non-Hispanic whites. Hispanics were also less likely to report vaping nicotine.
The prevalence of e-cigarette use among US youth increased dramatically during 2017-2019, partly due to the rising popularity of products with nicotine salt and pod-based products like JUUL, and a large number of flavors appealing to adolescents. The nationwide increases in use led the US Surgeon General to issue an advisory about the epidemic in 2018, but much more needs to be done to reverse the upward trend. Due to the recent spate of vaping-related lung injuries, calls for restrictions on flavored vaping products and e-cigarette use have become more urgent. Identifying substances vaped by youth is critical to formulating, implementing, and evaluating population-wide strategies and interventions to curb youth use of these products.
“Continuous surveillance of youth behaviors and strategies and interventions to reduce youth e-cigarette use are needed. The truth is that no form of tobacco is safe,” added co-investigator Mohammad Siahpush, PhD, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Story From EurekAlert
Psychedelics: The Next Wave For Investors?
Magic mushrooms, LSD, MDMA and the like could be game-changers for mental health.
It’s a wild time to invest in alternative medicine — just think about how much wealth has come from the widespread legalization of CBD and expanded access to full-spectrum cannabis in recent years. As we observe the successes and failures from these first-wave ventures, investors are now identifying a natural link to the early (yet potentially explosive) world of commercial psychedelics.
Why? Similarly to how people are using cannabis and CBD to treat themselves, these compounds are positioned to become the next big thing in mental health treatment.
Psilocybin, LSD and MDMA are being recommended as potential treatments for anxiety, depression and C/PTSD by a growing number of reputable institutions, with research indicating that these compounds could also have far-reaching effects for people struggling with substance abuse, smoking addiction or processing grief. The psychedelic-psychiatric breakthrough happens when you take one of these drugs, resulting in a dissolution of the ego, which can lead to a new perception of reality and one’s place within it.
Wherever You Go, There You Are
Scientist Albert Hofmann, the first known person to synthesize LSD (and several other powerful psychedelic compounds), argued passionately against the public’s casual recreational use of these drugs during the 1960’s and 1970’s. Hofmann’s initial discovery of LSD was set aside for five years until April 1943, when he returned to his earlier therapeutic research on the compound.
At the core of Hoffmann’s theory is the idea that psychedelics can aid an individual in readjusting their perspective, ultimately leading them to the realization that they are a small part of something much, much bigger than themselves. Side effects of this experience can include feeling deeply connected, an increase in empathy, confidence to approach situations in a new way and a reinvigorated sense of purpose. This reframing can be a powerful tool in the psychological treatment process. Similar to CBT or EMDR, psychedelics are being looked at as a kind of hard reset for patients living with a wide variety of complex mood disorders. For many people, the “trip” can be a life-changing experience.
A Long, Strange Trip Begins
Researchers are already discovering the great potential psychedelics have for public health.
Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (or MAPS), has been working the line between psychedelics and psychotherapy since 1986. Doblin’s team is focused on advancing critical professional dialogue around the study of psychedelics as a treatment aid for trauma, PTSD, schizophrenia, depression and more. It’s essential to support research from institutions like MAPS to help legitimize, understand and properly apply psychedelic treatments in psychotherapy.
Johns Hopkins University recently opened a new Center for Psychedelic Research thanks to a $17 million gift from donors. Paul B. Rothman, Dean of the Medical Faculty at the Johns Hopkins University School of Medicine and CEO of John Hopkins Medicine, is optimistic about this new field of medical, psychiatric and pharmaceutical research. “Our scientists have shown that psychedelics have real potential as medicine,” he said, “…and this new center will help us explore that potential.”
More Questions Than Answers
It’s natural at this stage to feel apprehensive in regards to investment in a new pharmaceutical sector. Is it legal? Does the industry have financial backing? How do you even begin to find a scientist to work on a project like this? Let’s take a look at where we are in North America today.
Denver, Co. and Oakland, Ca. both recently decriminalized possession of psilocybin, and legislation has already been drafted in many other locations across the United States.
Canada’s first psychedelic VC fund, FieldTrip Ventures, recently launched. The goal of a fund like this is to have products ready to launch in the days and weeks leading up to legalization, proving that the “early days” of this emerging market are already here.
Pharmaceutical companies are already actively developing psychedelic patents. Earlier this year, the U.S. Food & Drug Administration approved Johnson & Johnson’s ketamine-derived nasal spray, Spravato, for treatment-resistant depression.
ATAI Life Sciences is an interesting case, as the founder’s family offices (Apeiron Investment Group, HCS, Galaxy Financial) seed funded the start-up in 2018. ATAI recently closed a Series B financing, and has raised $80 million to continue research and development within the space.
Minimize Risk When Investing In Futuristic Technology
Think Clinically. Governments will likely try to keep experimentation limited to highly controlled, supervised scientific environments. To make the case for effective treatment of extremely complex psychiatric disorders, it’s critical to couple psychedelic drug therapy with talk therapy or professional therapeutic guidance, so it’s also likely that states will have to require a kind of rehab-like protocol for administering the drug to collect research. These in-patient facilities (or maybe even an on-call shaman), will become the dispensaries and delivery services of the psychedelic realm.
Embrace Science. Scientists and researchers are the most necessary element in building a case for the legalization and commercialization of psychedelics. Many cultures over thousands of years have created supervised ritual journeys based on the psychedelic journey, yet one common truth remains: scientific regulation is a very necessary step on the industry’s trip to success. Even as we speak, scientists are engineering bacteria to produce biologically-derived, lab-grown psilocybin, and there is a huge opportunity for entrepreneurs to improve upon the delivery method of these compounds.
Only Invest In Brands And People Who Execute. Talent matters more than the idea. Early entrants in the psychedelic capital game are fortunate to have proven business models from the recent commercialization of the cannabis industry to work from, and shouldn’t be afraid to hire talent from the cannabis industry. If investing, find a team or project that is mission-aligned, loves the work and is committed to building successful ventures in this new industry; even if it’s from the ground up.
Story from Greenwichtime.com
Chart – Cannabis and Psilocybin
The top 4 health benefits of magic mushrooms
As autumn turns to winter, this is the season when many enthusiasts head to wilder parts of the country and spend hours walking methodically around looking at the ground. The object of their desire is the mysterious little fellows we call the Liberty Cap – the UK’s indigenous hallucinogen.
Magic mushrooms are found all over the world and almost every culture has a historic, sacred relationship with these important medicines. For example, there is evidence in the form of stone paintings that Saharan aboriginal tribes of North Africa might have been using mushrooms from around 9000 BC.
Today in the UK the magic mushroom foraging season has increased due to climate change from about 33 days of autumn fruiting to more than 70. Prof Lynne Boddy, a fungal ecologist says –
“Climate change has had a dramatic effect on the fruiting season, every year the start and end of the season is dependent on the weather, and we can see that up until the late 1970s it was largely consistent. However, on average, the first fruiting date now comes much earlier in the year than previously, while the last fruiting comes later.”
Some people forage them simply for the pleasurable effects of euphoria induced following consumption. For others, they use the fungus as a means to gain spiritual insights and new knowledge. Interestingly, anecdotal tales of the benefits of eating magic mushrooms is now being supported and extended by new scientific research.
It turns out the witches, druids, pagans and hippies were right – eating magic mushrooms is good for you… here’s why –
4. Increase of “openness” and other beneficial shifts in personality
Humans our born open and full of love – eager to: connect, learn and grow as sentient beings. Over the course of our lives, experiences that may cause suffering close us down. Obvious examples include when we get our heart broken – we may be less open to future romantic encounters. People who have a series of negative events associated with aspects of their lives can close down to the detriment of future experiences.
Clearly where this learning protects us, it is useful, but in many cases we may close down more than we need to and we limit our life potential by shutting out new experiences and opportunities. In these cases psilocybin can help.
In a 2011 study, researchers found “significant increases in Openness following a high-dose psilocybin session.” Openness is a psychological term for someone’s attitude toward new experiences, and is associated with traits like imagination, creativity and aesthetic appreciation. Not only did openness generally rise during a psilocybin session, but in nearly 60 percent of study participants, it remained significantly higher than baseline for more than 1 year after the session.
3. Smoking cessation and other addictions
If you are caught up with unhealthy patterns in your life psychedelics can help. Magic mushrooms have been shown to help treat addiction to habit-forming drugs like cocaine and nicotine.
In 2008, Amanda Feilding of The Beckley Foundation initiated a collaboration with Johns Hopkins University on a pilot study investigating psilocybin-assisted psychotherapy to overcome nicotine addiction. With continued support from the Heffter Research Institute, the ongoing research is strengthening the case for psilocybin as a breakthrough treatment for substance abuse disorders.
2. Reduce depression
Psilocybin, the active ingredient in psychoactive mushrooms, has provided the spiritual and cultural bedrock of many great civilisations. The Aztecs referred to teonanácatl, which translates as ‘divine mushroom’, and modern neuroscience has revealed how psilocybin interacts with serotonin receptors in the brain in order to produce a range of consciousness-altering effects.
New research demonstrates how effective magic mushrooms can be at treating depression. In some cases, one dose can be enough to alleviate the symptoms permanently.
1. Dissolve’ your ego and increase creativity
Psychedelics in general and psilocybin specifically can enable states where our conscious experience of the world is freed from its association with our specific ego which may be revealed to be an illusory construct. A 2017 study, temporary ego loss could be beneficial in the right context. These expansive, sometimes life-changing experiences help us to feel profoundly connected and alive. They also boost creativity.
Story from Ecohustler
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium
Science 27 Sep 2019:
Genetic roots of multiple sclerosis
The genetics underlying who develops multiple sclerosis (MS) have been difficult to work out. Examining more than 47,000 cases and 68,000 controls with multiple genome-wide association studies, the International Multiple Sclerosis Genetics Consortium identified more than 200 risk loci in MS (see the Perspective by Briggs). Focusing on the best candidate genes, including a model of the major histocompatibility complex region, the authors identified statistically independent effects at the genome level. Gene expression studies detected that every major immune cell type is enriched for MS susceptibility genes and that MS risk variants are enriched in brain-resident immune cells, especially microglia. Up to 48% of the genetic contribution of MS can be explained through this analysis.
Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system (CNS) that often presents in young adults. Over the past decade, certain elements of the genetic architecture of susceptibility have gradually emerged, but most of the genetic risk for MS remained unknown.
Earlier versions of the MS genetic map had highlighted the role of the adaptive arm of the immune system, implicating multiple different T cell subsets. We expanded our knowledge of MS susceptibility by performing a genetic association study in MS that leveraged genotype data from 47,429 MS cases and 68,374 control subjects. We enhanced this analysis with an in-depth and comprehensive evaluation of the functional impact of the susceptibility variants that we uncovered.
We identified 233 statistically independent associations with MS susceptibility that are genome-wide significant. The major histocompatibility complex (MHC) contains 32 of these associations, and one, the first MS locus on a sex chromosome, is found in chromosome X. The remaining 200 associations are found in the autosomal non-MHC genome. Our genome-wide partitioning approach and large-scale replication effort allowed the evaluation of other variants that did not meet our strict threshold of significance, such as 416 variants that had evidence of statistical replication but did not reach the level of genome-wide statistical significance. Many of these loci are likely to be true susceptibility loci. The genome-wide and suggestive effects jointly explain ~48% of the estimated heritability for MS.
Using atlases of gene expression patterns and epigenomic features, we documented that enrichment for MS susceptibility loci was apparent in many different immune cell types and tissues, whereas there was an absence of enrichment in tissue-level brain profiles. We extended the annotation analyses by analyzing new data generated from human induced pluripotent stem cell–derived neurons as well as from purified primary human astrocytes and microglia, observing that enrichment for MS genes is seen in human microglia, the resident immune cells of the brain, but not in astrocytes or neurons. Further, we have characterized the functional consequences of many MS susceptibility variants by identifying those that influence the expression of nearby genes in immune cells or brain. Last, we applied an ensemble of methods to prioritize 551 putative MS susceptibility genes that may be the target of the MS variants that meet a threshold of genome-wide significance. This extensive list of MS susceptibility genes expands our knowledge more than twofold and highlights processes relating to the development, maturation, and terminal differentiation of B, T, natural killer, and myeloid cells that may contribute to the onset of MS. These analyses focus our attention on a number of different cells in which the function of MS variants should be further investigated.
Using reference protein-protein interaction maps, these MS genes can also be assembled into 13 communities of genes encoding proteins that interact with one another; this higher-order architecture begins to assemble groups of susceptibility variants whose functional consequences may converge on certain protein complexes that can be prioritized for further evaluation as targets for MS prevention strategies.
We report a detailed genetic and genomic map of MS susceptibility, one that explains almost half of this disease’s heritability. We highlight the importance of several cells of the peripheral and brain resident immune systems—implicating both the adaptive and innate arms—in the translation of MS genetic risk into an auto-immune inflammatory process that targets the CNS and triggers a neurodegenerative cascade. In particular, the myeloid component highlights a possible role for microglia that requires further investigation, and the B cell component connects to the narrative of effective B cell–directed therapies in MS. These insights set the stage for a new generation of functional studies to uncover the sequence of molecular events that lead to disease onset. This perspective on the trajectory of disease onset will lay the foundation for developing primary prevention strategies that mitigate the risk of developing MS.
The MS genetic map implicates microglia as well as multiple different peripheral immune cell populations in the onset of the disease. We list some of the immune cells in which we found an excess of MS susceptibility genes, implicating these cells as contributing to the earliest events that trigger MS. The sample size of our genome-wide association study is listed along with a circus plot illustrating main results.
Story from ScienceMag.org
Psilocybin Sessions: Psychedelics could help people with addiction and anxiety
Study participants at some of the country’s leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less
October 13, 2019 – Anderson Cooper
For most of us, psychedelic drugs conjure up images of the 1960’s. Hippies tripping out on LSD or magic mushrooms. But these powerful, mind-altering substances are now being studied seriously by scientists inside some of the country’s foremost medical research centers. They’re being used to treat depression, anxiety and addiction.
The early results are impressive, as are the experiences of the studies’ volunteers who go on a six-hour, sometimes terrifying, but often life-changing psychedelic journey deep into their own minds.
Carine McLaughlin: (LAUGH) People ask me, “Do you wanna do it again?” I say, “Hell no. I don’t wanna go do that again.”
Anderson Cooper: It was really that bad?
Carine McLaughlin: Oh, it was awful. The entire time, other than the very end and the very beginning, I was crying.
Carine McLaughlin is talking about the hallucinogenic experience she had here at Johns Hopkins University, after being given a large dose of psilocybin, the psychedelic agent in magic mushrooms, as part of an ongoing clinical trial.
Roland Griffiths: We tell people that their experiences may vary from very positive to transcendent and lovely to literally hell realm experiences.
Anderson Cooper: Hell realm?
Roland Griffiths: As frightening an experience as you have ever had in your life.
That’s scientist Roland Griffiths. For nearly two decades now, he and his colleague Matthew Johnson have been giving what they call “heroic doses” of psilocybin to more than 350 volunteers, many struggling with addiction, depression and anxiety.
Anderson Cooper: Can you tell who is going to have a bad experience, who’s gonna have a transcendent experience?
Roland Griffiths: Our ability to predict that is almost none at all.
Anderson Cooper: Really?
Matthew Johnson: About a third will– at our– at a high dose say that they have something like that, what folks would call a bad trip. But most of those folks will actually say that that was key to the experience.
Carine McLaughlin was a smoker for 46 years and said she tried everything to quit before being given psilocybin at Johns Hopkins last year. Psilocybin itself is non-addictive.
Anderson Cooper: Do you remember what, like, specifically what you were seeing or?
Carine McLaughlin: Yes. The ceiling of this room were clouds, like, heavy rain clouds. And gradually they were lowering. And I thought I was gonna suffocate from the clouds.
That was more than a year ago; she says she hasn’t smoked since. The study she took part in is still ongoing, but in an earlier, small study of just 15 long-term smokers, 80% had quit six months after taking psilocybin. That’s double the rate of any over-the-counter smoking cessation product.
Roland Griffiths: They come to a profound shift of world view. And essentially, a shift in sense of self that I think–
Anderson Cooper: They– they see their life in a different way?
Roland Griffiths: Their world view changes and– and they are less identified with that self-narrative. People might use the term “ego.” And that creates this sense of freedom.
And not just with smokers.
Jon Kostakopoulos: Beer usually, cocktails, usually vodka sodas, tequila sodas, scotch and sodas.
Jon Kostakopoulos was drinking a staggering 20 cocktails a night and had been warned he was slowly killing himself when he decided to enroll in another psilocybin trial at New York University. During one psilocybin session, he was flooded with powerful feelings and images from his past.
Jon Kostakopoulos: Stuff would come up that I haven’t thought of since they happened.
Anderson Cooper: So old memories that you hadn’t even remembered came back to you?
Jon Kostakopoulos: I felt, you know, a lot of shame and embarrassment throughout one of the sessions about my drinking and how bad I felt for my parents to put up with all this.
He took psilocybin in 2016. He says he hasn’t had a drink since.
Anderson Cooper: Do you ever have a day where you wake up and you’re like, man, I wish I could have a vodka right now or beer?
Jon Kostakopoulos: Never.
Anderson Cooper: Not at all?
Jon Kostakopoulos: Not at all, which is the craziest thing because that was my favorite thing to do.
Using psychedelic drugs in therapy is not new. There were hundreds of scientific studies done on a similar compound – LSD – in the 1950’s and 60’s. It was tested on more than 40,000 people, some in controlled therapeutic settings like this one. But there were also abuses. The U.S. military and CIA experimented with LSD sometimes without patients knowledge.
Fear over rampant drug use and the spread of the counterculture movement, not to mention Harvard professor Timothy Leary urging people to turn on, tune in and drop out, led to a clamp down.
In 1970, President Richard Nixon signed the controlled substances act and nearly all scientific research in the U.S. Into the effects of psychedelics on people stopped. It wasn’t until 2000 that scientist Roland Griffiths won FDA approval to study psilocybin.
Roland Griffiths: This whole area of research has been in the deep freeze for 25 or 30 years. And so as a scientist, sometimes I feel like Rip Van Winkle.
Anderson Cooper: And once you saw the results…
Roland Griffiths: Yeah. The red light started flashing. This is extraordinarily interesting. It’s unprecedented and the capacity of the human organism to change. It just was astounding.
Anderson Cooper: It sounds like you are endorsing this for everybody.
Roland Griffiths: Yeah, let’s be really clear on that. We are very aware of the risks, and would not recommend that people simply go out and do this.
Griffiths and Johnson screen out people with psychotic disorders or with close relatives who have had schizophrenia or bipolar disorder. Study volunteers at Johns Hopkins are given weeks of intensive counseling before and after the six-hour psilocybin experience; the psilocybin is given in a carefully controlled setting one to three times. To date, they say there’s not been a single serious adverse outcome.
We were told we couldn’t record anyone participating in the study while they were on psilocybin because it might impact their experience, but we were shown how it begins – without the psilocybin.
You lay on a couch, with a blindfold to shut out distractions and headphones playing a mix of choral and classical music – a psychedelic soundtrack with a trained guide, mary cosimano, watching over you.
Everything is done the same way it was for the LSD experiments scientists conducted in the 1950s and 60s. Some of the most dramatic results have been with terminal cancer patients struggling with anxiety and paralyzing depression.
Kerry Pappas: I start seeing the colors and the geometric designs and it’s like ‘oh this is so cool, and how lovely’ and, and then, boom. Visions began.
Kerry Pappas was diagnosed with stage III lung cancer in 2013. During her psilocybin session, she found herself trapped in a nightmare her mind created.
Kerry Pappas: An ancient, prehistoric, barren land. And there’s these men with pickaxes, just slamming on the rocks. So…
Anderson Cooper: And this felt absolutely real to you?
Kerry Pappas: Absolutely real. I was being shown the truth of reality. Life is meaningless, we have no purpose. And then I look and I’m still like a witness, a beautiful, shimmering, bright jewel. And then it was sound, and it was booming, booming, booming. Right here right now.
Anderson Cooper: That was being said?
Kerry Pappas: Yes. “You are alive. Right here right now, because that’s all you have.” And that is my mantra to this day.
Michael Pollan: It seemed so implausible to me that a single experience caused by a molecule, right, ingested in your body could transform your outlook on something as profound as death. That’s– that’s kind of amazing.
Author Michael Pollan wrote about the psilocybin studies in a bestselling book called “How to Change Your Mind.” As part of his research, he tried psilocybin himself with the help of an underground guide.
Anderson Cooper: The kind of things that cancer patients were saying, like, “I touched the face of God.” You were skeptical about when you hear phrases like that?
Michael Pollan: Yeah. Or, “Love is the most important thing in the universe.” When someone tells me that I’m just like, “yeah, okay.”
Anderson Cooper: So you don’t go for some of the phrases that are used?
Michael Pollan: No. It gives me the willies as a writer. And I really struggled with that cause during one of my experiences I came to the earth-shattering conclusion that love is the most important thing in the universe. But it’s, that’s Hallmark card stuff, right? And um, so…
Anderson Cooper: And yet while you were on it and afterward…
Michael Pollan: It was profoundly true. And it is profoundly true. Guess what? Um…
Anderson Cooper: There’s a reason it’s on a Hallmark card.
Michael Pollan: There is a reason. And one of the things psychedelics do is they peel away all those essentially protective levels of irony and, and cynicism that we, that we acquire as we get older and you’re back to those kind of “Oh, my God. I forgot all about love.” (Laugh)
Pollan said he also experienced what the researchers describe as ego loss, or identity loss – the quieting of the constant voice we all have in our heads.
Michael Pollan: I did have this experience of seeing my ego– burst into– a little cloud of Post-It notes. I know it sounds crazy.
Anderson Cooper: And what are you are without an ego?
Michael Pollan: You’re, uh… (Laugh) You had to be there.
Researchers believe that sensation of identity loss occurs because psilocybin quiets these two areas of the brain that normally communicate with each other. They’re part of a region called the default mode network and it’s especially active when we’re thinking about ourselves and our lives.
Michael Pollan: And it’s where you connect what happens in your life to the story of who you are.
Anderson Cooper: We all develop a story over time about what our past was like and who we are.
Michael Pollan: Right. Yeah, what kind of person we are. How we react. And the fact is that interesting things happen when the self goes quiet in the brain, including this rewiring that happens.
To see that rewiring, Johns Hopkins scientist Matthew Johnson showed us this representational chart of brain activity. The circle on the left shows normal communication between parts of the brain, on the right, what happens on psilocybin. There’s an explosion of connections or crosstalk between areas of the brain that don’t normally communicate.
Anderson Cooper: The difference is just startling.
Matthew Johnson: Right.
Anderson Cooper: Is that why people are having experiences of– seeing you know, repressed memories, or past memories, or people who have died or?
Matthew Johnson: That’s what we think. And even the perceptual effect, sometimes the synesthesia, like, the– the seeing sound.
Anderson Cooper: People see sound?
Matthew Johnson: Yeah, sometimes.
Anderson Cooper: I– I don’t even know what that means.
Matthew Johnson: Right, yeah. (LAUGH) It’s– it’s–
Michael Pollan: Maybe the ego is one character among many in your mind. And you don’t necessarily have to listen to that voice that’s chattering at you and criticizing you and telling you what to do. And that’s very freeing.
It was certainly freeing for Kerry Pappas. Though her cancer has now spread to her brain, her crippling anxiety about death is gone.
Kerry Pappas: Yeah, it’s amazing. I mean, I feel like death doesn’t frighten me. Living doesn’t frighten me. I don’t frighten me. This frightens me.
Anderson Cooper: This interview frightens you, but death doesn’t?
Kerry Pappas: No.
It turns out most of the 51 cancer patients in the Johns Hopkins study experienced “significant decreases in depressed mood and anxiety” after trying psilocybin. Two-thirds of them rated their psilocybin sessions as among the most meaningful experiences of their lives. For some, it was on par with the birth of their children.
Kerry Pappas: To this day, it evolves in me.
Anderson Cooper: It’s still alive in you–
Kerry Pappas: It’s still absolutely alive in me.
Anderson Cooper: Does it make you happier?
Kerry Pappas: Yeah. And– and I don’t necessarily use the word happy.
Kerry Pappas: Comfortable. Like, comfortable. I mean, I’ve suffered from anxiety my whole life. I’m comfortable. That, to me, okay. I can die. I’m comfortable. (LAUGH) I mean, it’s huge. It’s huge.
Produced by Sarah Koch. Associate producer, Chrissy Jones
Story from 60 Minutes CBS News
Why Do Magic Mushrooms Cause “The Yawns”?
The serotonin 5-HT2C receptor may play a key role.
Excessive yawning is a side effect many people experience when they ingest psilocybin mushrooms (aka magic mushrooms). For some, it’s just annoying. For others, it’s a real distraction from their experience. In contrast, some people anticipate yawning and look forward to it because it lets them know the compounds in the mushrooms are coursing through their veins. But, what is it about magic mushrooms that cause yawning in some people?
What is a Yawn and Why Do People Do It?
Before delving into yawning and magic mushrooms, it’s best to understand what yawning is and why people yawn at all. Various research papers define yawning something like this; a long inspiration and rapid expiration that is accompanied by a “coordinated motor pattern” of opening of the jaw, closing the eyes and contracting the muscles in the face. Yawns sometimes include stretching of the neck arms and trunk.
The exact location of a yawning center (also called the yawing network or yawning zone) in the human brain has not been experimentally proven. Current theories suggest that the areas involved include parts of the cortex, limbic system, hypothalamus, and brain stem.1 Scientists have learned from malformations and lesion studies that the core of the yawning center is located in the brain stem. Contagious yawning may arise from external pattern recognition in the neocortex, limbic system, and thalamus. Interestingly, several neurotransmitters and peptides have control over yawning. They include acetylcholine, dopamine, oxytocin, nitric oxide, excitatory amino acids, opioid peptides, and serotonin.1,2
Over the years, scientists have developed four main hypotheses (in addition to contagious yawning, see below) to explain why people yawn.1 They are the respiratory hypothesis, communication hypothesis, arousal hypothesis, and the brain-cooling hypothesis. More than one of these reasons may be at work in a given situation, and there are likely more yet undiscovered.
The respiratory hypothesis was first posed by the Dutch author Johannes de Gorter in 1725.3 He attributed the need for yawning “to a need for faster blood circulation and to cerebral anemia.” Other writers and scientists from that time until today have speculated that yawning was due at least in part to anemia and poor circulation in the brain, or as one early writing put it, “bad air in the lungs.” 1 Several modern-day studies support the idea that yawning is caused by a low oxygen level in the brain (cerebral hypoxemia) or excessive carbon dioxide in the blood (hypercapnia). Krestel et al. reviews and discusses these studies in a 2018 paper in Progress in Neurobiology.
The communication hypothesis is basically what it says. Yawning is a means of communicating tiredness and boredom between humans which synchronizes group behavior.4 It is interesting to note that people who view uninteresting and repetitive stimuli have been shown to yawn more frequently.5
According to experts, the arousal hypothesis and the brain-cooling hypothesis need more research to determine their validity.1 The arousal hypothesis contends that yawning is a biological response that helps regulate the waking state and activity level. Currently, the brain-cooling hypothesis of yawning is thought to be more valid in cats and dogs who do not exchange heat as effectively as humans via their body surface.
And, yes, scientific studies have shown that not only is yawning is contagious, but some people are more susceptible than others to contagious yawning. How it works in the brain is not completely understood, though. One study using transcranial magnetic stimulation (TMS) found that trying to resist yawning increases the urge to yawn. However, it doesn’t change a person’s propensity for contagious yawning.6 From these behaviors and the TMS data, the authors hypothesized that cortical excitability and physiological inhibition in the primary motor cortex may be the areas of the brain that control a person’s propensity for contagious yawning.
Is Yawning a Good or Bad Side Effect?
The term “side effect” carries with it connotations of unpleasantness and potential negative consequences. Although some magic mushroom users find yawning annoying or distracting or both, others anticipate and welcome it as part of the whole psychedelic experience. Here are some examples of comments from sites like Bluelight, Erowid, Shroomery, and Reddit.
“I find it’s really therapeutic. The yawning, crying, sweating etc… on shrooms. Its feels like all the pressure and energy is being released.”
“Some trips you get normal yawns, some you get the crazy long psychedelic yawns, I personally love that feeling intense yawns are the best.”
“Yeah I have yawns that like stretch my jaw when I’m tripping balls, weird feeling, doesn’t feel like a normal yawn. One time I thought I got possessed by mushrooms because of this.”
Interestingly, information from experience reports and online discussion boards indicates that yawning often occurs on the “come up.” This observation could be important for understanding the pharmacology of magic mushroom components. Here are some examples:
“That’s [yawning is] always the sign for me that things are setting into waking dreamworld.”
“I have noticed a pattern that [yawning] happens more often than not when I ingest shrooms, where an exponential increase in the amount of yawns I experience occurs as I approach the peak of the trip. The closer I get to the peak, the more im yawning, and the less I am able to control it.”
“I’m kinda used to it, but I know when the come-up is about to start because I get the yawns.”
“Yeah, on the come-up and the first hour or so it’s yawn city.”
“I yawn a lot during the come up of tryptamines (especially psilocybin and 4-aco-mipt), but once through the come up, the yawns stop.”
Magic Mushrooms and Excessive Yawning
There are no scientific studies directly examining why magic mushrooms or the compounds in them cause some people to yawn excessively. However, revealing some hints may be possible by extrapolating what is known about the physiology of yawing to the compounds found in magic mushrooms, particularly psilocybin analogs like serotonin and other derivatives, and how well they bind to serotonin receptors.
The involvement of serotonin in causing yawning was first proposed in 1979 in studies using rats.7 Since that time, additional research has found that serotonin binding to 5-HT2C receptors is likely the conduit that results in yawing in humans.8 The binding of agonist compounds to 5-HT2C has been found to increase yawning in a dose-dependent manner, and the binding of antagonists to the receptor reduces yawning.
The next piece of information needed for this analysis is data indicating if and how well compounds in magic mushrooms bind to the 5-HT2C receptor. The PDSP Ki database maintained by the US National Institute of Mental Health contains binding affinity data for hundreds of compounds and molecular targets. In particular, the binding inhibition constant, Ki indicates how strongly a compound binds to a receptor. Lower Ki values indicate less binding inhibition and higher binding affinity for a receptor.
For example, the Ki for serotonin on the human 5-HT2C receptor is anywhere from 2.0 – 56.0 nM depending on the test conditions. Psilocybin’s Ki value at 5-HT2C is >10,000 nM. This makes sense based on what is known about psilocybin being a prodrug of psilocin, meaning psilocybin should have a higher Ki and hence a less affinity for the receptor. And then there’s psilocin. It’s Ki at 5-HT2C is around 97.0 nM, meaning it has a greater affinity for the receptor than psilocybin, which also makes sense. But back to the point of yawning, these data indicate that psilocin could cause yawning even though its affinity for the 5-HT2C receptor is less than that of serotonin.
Scientists know that different compounds can have different effects when binding to the same receptors. For example, the neurotransmitter serotonin elicits feelings of well-being and happiness when it binds to the 5-HT2A receptor. Serotonin also modulates learning, memory, and a myriad of physiological processes.9 In contrast, the magic mushroom agonist compound psilocin (the active dephosphorylated version of psilocybin) causes the psychedelic effect when it binds to 5-HT2A.10 However, it is conceivable that the binding of magic mushroom agonist compounds to serotonin receptors could elicit a response similar to serotonin, e.g., causing yawning by binding to 5-HT2C. Another intriguing fact to ponder in this context is that all known psychedelic compounds are agonists at both the 5-HT2A and 5-HT2C receptors.11 Searching through discussion boards and experience reports reveals that yawning is also a side effect reported by people using LSD and 4-AcO-DMT.
It’s important to note that there are scattered reports on discussion boards of people yawning after ingesting a species of magic mushrooms but not the next time. This could be due to the chemical variability between batches of mushrooms that is brought on by soil conditions, climate, and other variables. It could also be related to the physical health and metabolism of the user.
The Bigger Picture – What Does This Mean?
The side effects of magic mushrooms such as yawning pose issues when using whole extracts from the plant flesh or the mushrooms themselves for therapeutic use. Granted, yawning is not a serious side effect and may be more of an annoyance for most people. However, any side effect could be better understood and possibly controlled by studying the individual compounds in magic mushrooms along with the entourage effect between the components. It’s also important to know from a physiological standpoint why magic mushrooms cause yawning and some people. What it comes down to is formulations containing precise amounts of certain compounds may prevent many side effects and may also result in more effective therapies and user experiences.
One Mystical Psychedelic Trip Can Trigger Lifelong Benefits
New research corroborates how taking psilocybin once forever changed my outlook.
Apr 28, 2019
As a science reporter and blogger in the digital age, I keep my antennae up for research trends and look for patterns that capture the zeitgeist of this era and reflect our collective unconscious. One noteworthy parallelism I observed this month is between two research papers that address religion, spirituality, and life satisfaction from different angles—but reach similar conclusions.
The first paper, “Oneness Beliefs and Their Effect on Life Satisfaction,” was written by Laura Marie Edinger-Schons of the University of Mannheim in Germany and published April 11 in Psychology of Religion and Spirituality.
The second paper (that in my opinion complements Edinger-Schons “oneness beliefs = greater life satisfaction” hypothesis) is by researchers from Johns Hopkins University School of Medicine in Baltimore, “Survey of Subjective “God Encounter Experiences”: Comparisons Among Naturally Occurring Experiences and Those Occasioned by the Classic Psychedelics Psilocybin, LSD, Ayahuasca, or DMT,” and was published April 23 in PLOS ONE.
The chronological timeline of these two April 2019 papers from peer-reviewed journals and my reportage on their empirical findings has evolved over the past two weeks. On April 13, I wrote a post about Edinger-Schons work, “Does ‘Flow’ Open Our Minds to Believing in ‘Oneness’?”
My initial post on this topic framed her findings on increased oneness beliefs being linked to greater life satisfaction through the lens of flow. In her paper, Edinger-Schons speculates that losing oneself in an ego-dissolving state of flow may be a secular way for each of us to nourish stronger “oneness beliefs” over time, regardless of someone’s religion. I concur. (See, “What Driving Forces Help Us Go From ‘Flow’ to Superfluidity?”)
After digesting the Edinger-Schons paper, I realized that the triad of (1) manifesting a state of flow/superfluidity regularly through sports, (2) experiencing sublime awe in nature, and (3) a mystical psilocybin trip during adolescence had cemented my lifelong oneness beliefs. Over Easter Weekend, I wrote a post, “Psilocybin, Sublime Awe, and Flow Made “Oneness” My Religion,” that unpacked the genesis of my lifelong oneness beliefs based on these three interconnected factors. I published that post on April 20.
Serendipitously, my faith in Carl Jung’s concept of synchronicity and “meaningful coincidences” was corroborated on April 23, when, out-of-the-blue, I received an email blast from the Johns Hopkins University newsroom, “Experiences of ‘Ultimate Reality’ or ‘God’ Confer Lasting Benefits to Mental Health.” In a woo-woo, Twilight Zone kind of way, reading this study (Griffiths et al., 2019) about the long-term psychological benefits of having “ultimate reality” or so-called “God encounter experiences” (with or without psychedelics) gave me goosebumps because it provided evidence-based affirmation of so many things I’d tried to articulate a few days earlier based solely on my anecdotal, autobiographical experiences.
The new research by Roland Griffiths and colleagues at Johns Hopkins reaffirms the universal ability of one mystical psychedelic trip or having a profound “God encounter” without drugs to improve life satisfaction and psychological well-being for an indefinite amount of time.
Interestingly, Griffiths and colleagues found that over 66 percent of people who self-identified as atheists before having an “ultimate reality” or “God of your understanding” experience (with or without the use of psychedelics) no longer considered themselves atheists after having some type of “God encounter experience.”
“Experiences that people describe as encounters with God or a representative of God have been reported for thousands of years, and they likely form the basis of many of the world’s religions,” lead researcher Roland Griffiths, who is a professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, said in a statement. “And although modern Western medicine doesn’t typically consider ‘spiritual’ or ‘religious’ experiences as one of the tools in the arsenal against sickness, our findings suggest that these encounters often lead to improvements in mental health.”
Griffiths and his Johns Hopkins co-authors explain the design and terminology of their “Survey of Subjective ‘God Encounter Experiences'” in the paper’s introduction:
“The present study was undertaken to advance our understanding of both naturally occurring and psychedelic-occasioned religious experiences that are interpreted as an encounter with God (e.g., the God of your understanding), Higher Power, Ultimate Reality, or an Aspect or Emissary of God (e.g., an angel). [Nota bene: To simplify the writing of the present report, the term “God encounter experience” will be used as a label to refer to all four descriptive variants of these experiences. We have chosen to capitalize the word “God” to be consistent with the survey instructions and question wording.]
Most participants reported vivid memories of the encounter experience, which frequently involved communication with something having the attributes of being conscious, benevolent, intelligent, sacred, eternal, and all-knowing.”
Taken together, my interpretation of the latest empirical evidence on “Oneness Beliefs” and the four categories under the umbrella of “God Encounter Experiences” is that all of this terminology is using different words to describe the same phenomenon.
In my opinion, the main takeaway of these two April 2019 research papers by Edinger-Schons and Griffiths et al. is that psychedelic substances and flow states are both tools we can use to nourish our belief and connectedness to something much bigger than “I” or “me”—while simultaneously counteracting the global epidemic of “us” against “them” divisiveness that is often driven by religion.
There is an important caveat: Mystical psychedelic experiences can be extremely difficult. In a sub-section of their paper titled “God encounter experiences are not infrequently psychologically challenging” Griffiths et al. write:
“That such experiences may be both attractive and extremely difficult is consistent with the classic description of the dual nature of encounters with the “Holy” both as “mysterium tremendum” (referring to its awfulness and absolute overpoweringness) and “mysterium fascinans” (referring to its fascinating and attractive nature) by the theologian Rudolf Otto . Likewise, that psychedelic experiences can involve both positive emotion including transcendence as well as highly distressing feelings such as fear and insanity have been well-documented [29,49,50].”
As Edinger-Schons (2019) posits, flow is a universally accessible, drug-free way to open our eyes to the power of “oneness” and our human commonality in ways that transcend religious differences. Psychedelic substances can also facilitate this process, but come with many more risks and, in my opinion, are not a sustainable way to tap into a sense of connectedness on a daily basis—even when taken in “microdose” quantities. (See, “Psychedelic Microdosing: Study Finds Benefits and Drawbacks” and “This Is Your Brain on Microdoses of Psilocybin.”)
For their recent study, the Johns Hopkins researchers conducted international online surveys that asked a total of 4,285 people around the globe to recall their most memorable encounter with a “higher power,” “ultimate reality,” “God of their understanding,” or “an aspect or representative of God, such as an angel.” They also asked survey respondents how they felt this experience had changed their lives.
There were two different 50-minute surveys. One survey was filled out by participants who had used psychedelics in the past; the other “non-drug” survey was for respondents who hadn’t ever tried psilocybin, ayahuasca, LSD, or DMT.
A total of 3,476 people responded to the psychedelics survey and 809 responded to the non-drug survey. Those who reported having a “God encounter” experience on psychedelics tended to prefer the term “ultimate reality” experience. Below is a bullet point list of other findings from this study provided in the Johns Hopkins press release:
- About 75 percent of respondents in both the non-drug and psychedelics groups rated their “God encounter” experience as among the most meaningful and spiritually significant in their lifetime, and both groups attributed to it positive changes in life satisfaction, purpose, and meaning.
- Independent of psychedelics use, more than two-thirds of those who said they were atheists before the experience no longer identified as such afterward.
- Most participants, in both the non-drug and psychedelics groups, reported vivid memories of the encounter experience, which frequently involved communication with some entity having the attributes of consciousness (approximately 70 percent), benevolence (approximately 75 percent), intelligence(approximately 80 percent), sacredness (approximately 75 percent) and eternal existence (approximately 70 percent).
- Although both groups reported a decreased fear of death, 70 percent of participants in the psychedelics group reported this change, compared with 57 percent among non-drug respondents.
- In both groups, about 15 percent of the respondents said their experience was the most psychologically challenging of their lives.
- In the non-drug group, participants were most likely to choose “God” or “an emissary of God” (59 percent) as the best descriptor of their encounter, while the psychedelics group were most likely (55 percent) to choose “ultimate reality.”
Reading the final bullet point on this list is a reminder of the innumerable minefields surrounding the word “God.” Back in October of 1959, Carl Jung got into some hot water when he was asked during a “Face to Face” interview on the BBC with John Freeman, “Do you now believe in God?” After a thoughtful pause, Jung famously responded, “It’s difficult to answer. I know. I don’t need to believe. I know.”
C.G. Jung’s “I know. I don’t need to believe. I know.” response to whether or not he believed in God ruffled a lot of feathers in the religious community.
As someone who has had “God encounter” experiences both with and without psychedelics and under both secular and religious circumstances, I understand what Jung is trying to say on an intellectual and intuitive level. Once you’ve had any type of “conversion experience” that opens your eyes to the existence of Something (with a capital “S”) mystical and understand “oneness” as the interconnectedness of everything—you “KNOW” that there is some type of “God-like” existence in the universe.
Unfortunately, the semantics of finding appropriate language to describe these agnostic or religious “God” experiences often opens up a controversial can of worms. C.G. Jung addressed the backlash from referencing “God” the way he did during the BBC interview in a lengthy November 16, 1959 letter to a pastor named Valentine Brooke. In an excerpt from this letter published in The New God-Image: A Study of Jung’s Key Letters Concerning the Evolution of the Western God-Image, (p. 136 ) Jung writes:
“When I say that I don’t need to believe in God because I “know,” I mean I know the existence of God-images in general and in particular. I know it is a matter of universal experience and, in so far as I am no exception, I know that I have such experience, which I call God. So I say: “I know Him.” But why should you call this something “God”? I would ask: “Why not?” It has always been called “God.” An excellent and very suitable name indeed. Respice finem! I know what I want, but am doubtful and hesitant whether the Something is of the same opinion or not. Hoping I have succeeded in elucidating the puzzle. Sincerely yours, C.G. Jung”
Since temps immémorial, people from diverse worldwide cultures have described having profound mystical and religious “God” experiences while under the influence of psychedelic substances such as psilocybin-containing “magic mushrooms” or the Amazonian brew known as ayahuasca. There is growing evidence that these deeply meaningful encounters with “God” or an “ultimate reality” have healing properties that can last a lifetime after one “conversion” experience.
That being said, as a public health advocate: I do not condone the recreational use of psychedelic drugs. If you are considering trying any psychedelic substance, please make sure you’re in a safe place with a trustworthy support network and that you know exactly how many milligrams you’re consuming in relation to a “hallucinogenic dose” vs. “microdose” of that drug in relation to your body weight and how much food is in your stomach.
Although I had one mystical experience on psilocybin as an adolescent that hardwired my “oneness beliefs” and concepts of an “ultimate reality” in ways that I am eternally grateful to have encountered; I also had one terrifying “bad trip” that left some psychological scars and PTSD. Having one colossally bad trip (after ingesting a mega-dose of 5+ grams of dried magic mushrooms on an empty stomach) makes it impossible for me to even consider ever experimenting with psychedelic substances again.
“I don’t know if you’ve ever had a bad trip, but it feels like all the tumblers in your brain are turning and re-configuring; unlocking doors that should stay shut, closing windows that should stay open, all the while re-etching the blueprints of your psyche and the foundation of your soul. Psilocybin fuses your synapses into new configurations, permanently rearranging the architecture of your mind.” —Christopher Bergland in The Athlete’s Way: Sweat and the Biology of Bliss, 2007
Based on my life experience with accidentally ingesting way too many grams of psilocybin when I was still in high school, I agree that drug-based experiences with “Something Holy” can trigger both “mysterium tremendum” and “mysterium fascinans.” (See: “Psilocybin May ‘Reset’ Brain Circuitry of Depressed Patients” and “The Neuroscience of LSD Unlocks the Doors of Self-Perception.”)
You may be asking: “Based on the potential risks of ingesting psychedelic substances, is it worth it?” I cannot answer that question for you, but would recommend reading a highly informative April 25 post, “Your Questions About Psychedelics, Answered,” by fellow blogger Tom Shroder, author of Acid Test: LSD, Ecstasy, and the Power to Heal.
Doctors could tap ‘shrooms to relieve pain
Psychedelic medicine, long taboo, is moving toward the mainstream: Two new studies show the hallucinogenic drug psilocybin might relieve anxiety and depression in cancer patients.
Dozens of distressed patients, treated under controlled conditions at two prestigious medical centers, saw spirit-lifting effects that lasted at least several weeks after taking the “magic mushroom” drug, according to results published Thursday in The Journal of Psychopharmacology.
In an unusual move, the journal also published 10 commentaries from experts in psychiatry, end-of-life care and drug policy. The experts said the studies were small and preliminary, but all supported continued research. They suggest psilocybin, while still illegal outside of studies, is “well within the accepted scope of modern psychiatry,” said an editorial by David Nutt, a professor of neuropsychopharmacology at Imperial College, London.
But the benefits remain unconfirmed and largely unexplained, commentators said. Just how a hallucinogenic experience might lift anxiety and depression over weeks or months is “the $64,000 question,” said Jeffrey Lieberman, a past president of the American Psychiatric Association and chair of psychiatry at Columbia University. He co-wrote one of the commentaries calling for more studies.
The studies were conducted with 29 patients at New York University Langone Medical Center and 51 patients at Johns Hopkins University. All had advanced cancers and were anxious or depressed.
The research teams set up cozy living-room style clinics, where the patients were treated twice — once with a synthetic psilocybin dose strong enough to produce an hours-long hallucinogenic trip, and once with either a very low dose of psilocybin (at Johns Hopkins) or niacin, a vitamin that can cause warm, tingling sensations (at NYU). Some got the real thing first; others got the substitute first.
The treatments were five to seven weeks apart, allowing the researchers time to compare the first patients to get the real treatment with those who waited. Then they gave the hallucinogenic dose to the rest, and followed everyone for another six months.
During their psilocybin experiences, the patients wore eye masks and headphones and were urged to lie back, listen to soothing music and “direct their attention inward,” said research leader Roland Griffiths, a professor of behavioral biology at Johns Hopkins. Therapists sat nearby, ready to comfort those who became briefly anxious or afraid, which happened in about one-third of cases, he said.
Patients reported the dream-like visions and heightened emotions typically produced by psilocybin. In the days and weeks afterward, therapists helped them sort through what many saw as “mystical experiences” of connection and love, Griffiths said.
The reported result: immediate sharp declines in anxiety and depression in patients treated first, when compared with initially untreated patients. Those who got delayed treatment also improved, and up to 80% were less distressed at the end of the studies than at the beginning. However, because all patients eventually got the drug, there were no comparison groups after the first few weeks — making it impossible to say whether the drug deserved credit for the prolonged improvements.
But, in results from the first weeks, “the overall effect sizes are really quite startling relative to what you would expect with other interventions,” such as antidepressants, Griffiths said.
“These are some very rich, powerful, experiences,” said Stephen Ross, an associate professor of psychiatry who led the NYU study.
New York participant Patrick Mettes gained “a tremendous insight into his own personal journey” and came away feeling that “love was the most important thing,” said his wife, Lisa Callaghan. Mettes died of his cancer in 2012. In a journal entry written shortly after his psilocybin dose, he said that at the peak of his experience, he became “one with everything in the universe. It was simply, perfection.”
Don’t expect your average local hospital or hospice to be offering hallucinogenic trips any time soon. Any studies will require the permission of the Food and Drug Administration, the Drug Enforcement Administration and local review boards.
And you should not try this at home, researchers stressed — distancing themselves from a history in which psychedelic advocates such as Timothy Leary urged widespread use of LSD, psilocybin and other hallucinogens. Leary, a Harvard psychologist, started out using the drugs in legitimate studies but grew inpatient to spread them to the masses, urging young people to “turn on, tune in, drop out.” Widespread reports of dangerous reactions led to criminalization of the drugs and a decades-long pause in research.
“These are drugs that have real dark sides,” Ross said. Griffiths agreed. “These experiences can be dangerous for some vulnerable individuals,” including those with a history of psychosis, he said. Cases of “people jumping out of windows or running into traffic and getting run over,” do happen, he said.
But, he said, “we can administer these drugs safely to people who are carefully screened and supported before, during and after.”
Researchers have already started studies in other groups, including alcoholics and people trying to quit smoking.
The two new studies were funded by the non-profit Heffter Research Institute.
A team of Johns Hopkins researchers is calling for magic mushrooms to be made legally available as medicine
- Pending results from several ongoing clinical trials, the researchers called for psilocybin to be placed in the most lenient category by the Drug Enforcement Administration — alongside CBD, which was rescheduled last month, and cough syrup.
But earlier this year, some of the leading researchers at Johns Hopkins University — people who’ve pioneered some of the highest-caliber studies on psychedelics’ therapeutic mental health potential— suggested that’s what should happen for a drug derived from magic mushrooms.
In a recent article published in the medical journal Neuropharmacology, four preeminent psychiatrists wrote that psilocybin, the active ingredient in magic mushrooms, should be placed in the most lenient category by the Drug Enforcement Administration and made legally available through clinicians, pending final data from several ongoing clinical trials.
In essence, they argue, the potential benefits presented by psilocybin outweigh its possible harms.
The available evidence suggests they’re correct.
Although the DEA currently considers psilocybin a Schedule I drug “with no medical use,” the past decade has seen a resurgence of research on psychedelics’ therapeutic possibilities for treating psychiatric diseases like anxiety and depression. A large recent survey also suggested that magic mushrooms could be among the safest recreational drugs.
That suggests to several experts — including the authors of the recent article — that psilocybin should be handled differently than, say, heroin or bath salts (other Schedule I drugs).
“It is the opinion of the authors of this review that the original placement of psilocybin was the result of a substantial overestimation of the risk of harm and abuse potential,” they wrote.
The authors included Johns Hopkins University School of Medicine professors of psychiatry Matthew Johnson, Roland Griffiths, and Jack Henningfield; as well as Peter Hendricks, an associate professor of psychiatry at the University of Alabama at Birmingham’s School of Public Health.
A resurgence of interest in psychedelics as medicine
Over the past several years, a handful of studies have suggested that psychedelic drugs like psilocybin could help treat a range of mental illnesses, including anxiety, depression, drug addiction, and PTSD.
One of those studies — a clinical trial published in the Journal of Psychopharmacology in 2016 — was written by Griffiths and Johnson, two authors of the recent piece outlining why psilocybin should be made medically available. Griffiths’ and Johnson’s seminal work concluded that in people with a terminal cancer diagnosis, a single high dose of psilocybin appeared to help pull them out of severe depression and anxiety. On a press call after the study came out, Griffiths likened the treatment to “a surgical intervention” for the mental illnesses.
Since then, research into drugs like LSD, ecstasy, ketamine, and marijuana (which many experts consider to have psychedelic properties) has abounded. Last year, a study suggested that ecstasy could help veterans cope with PTSD symptoms. Another recent paper hinted that ketamine could be used to curb severe depression. Several more recent studies of psilocybin have suggested it might help treat obsessive-compulsive disorder as well.
“At this point, the data suggest that the potential therapeutic benefits of psilocybin-assisted therapy are real, and of potential medical and public health significance,” the four authors wrote in their recent article.
The findings on psychedelics are also garnering the attention of investors and tech moguls. Just last month, German entrepreneur Christian Angermeyer launched a new biotech company called Atai with the mission of backing more psychedelic mental health research. Compass Pathways, a research startup studying and producing psilocybin for depression, recently attracted backing from tech magnate Peter Thiel.
But the legal classifications of these drugs not be keeping adequate pace with the research or the investments.
‘Replacing fear and misinformation with scientifically based facts’
Despite the ongoing research, neither the Food and Drug Administration nor the DEA has announced an intent to reschedule psilocybin or any other psychedelic. But such a move could happen. It did recently with marijuana.
In June, the FDA approved the first medicine made with a compound from cannabis. Called Epidiolex, the drug treats two rare forms of epilepsy using CBD, a marijuana compound that’s not responsible for a high. As a result of the FDA’s green light, the DEA was forced to reclassify CBD.
“We don’t have a choice on that,” DEA public affairs officer Barbara Carreno told Business Insider in June. “It absolutely has to become Schedule 2, 3, 4, or 5.”
So this September, the DEA officially shifted its stance on marijuana for the first time in 46 years by putting CBD in Schedule 5 alongside substances like cough syrup and sleep aids — all drugs that the agency considers at the lowest risk of abuse or harm.
In their article on psilocybin, the authors write that it too should be placed in Schedule 5, pending its approval as a medicine. Some experts say that could happen as soon as 2027.
“Schedule I is for substances with a high potential for abuse, lack of therapeutic approval, and that cannot be used safely in medicine,” they write. “History of use and available scientific data show that the first criterion is questionable, and the third criterion is likely not true.”
Meanwhile, the research on psilocybin is continuing to blossom. Clinical trial results from Compass are expected before 2020; researchers at the University of California, San Francisco are currently enrolling patients in a study to see whether psilocybin could assist in group therapy to improve the mental health of long-term AIDS survivors; and scientists at New York University aim to study whether psilocybin could be used to treat alcoholism.
Johnson, Griffiths, Henningfield, and Hendricks seem to believe the future of those studies — and psilocybin’s potential — is bright.
“This area of regulatory science has the potential to facilitate innovative therapeutic breakthroughs by replacing fear and misinformation with scientifically based conclusions and facts,” they wrote.
Read more of our psychedelic medicine coverage:
Drug danger chart shows which drugs you should never mix, and which you totally should
Vices September 10, 2018 By Eleanor Gray
Nobody is perfectly healthy. We all need drugs. Sometimes a combination of drugs. We get them from drug dealers.
Your indoor drug dealers — the ones who wear white lab coats, take payment by insurance, and operate under florescent lights — know about drug combinations: which drug combos are synergistic and heighten each other’s effects, which combinations you gotta be careful with. And which can kill you. They have apps and charts and books on it.
Your outdoor drug dealers, the ones who wear tie-dye shirts, take payment in beer, and operate under overpasses, don’t got jack. They’ll tell you that dilaudid and Benadryl will send you flying, or molly and caffeine is deadly, or Budweiser and vicodin makes Calculus II tolerable. This is how people aspirate and croak.
Well, the outdoor drug dealers are catching up in knowledge.
Read this amazing chart. It has twenty-five of the most popular scheduled drugs listed. Your safer drugs, like LSD, mushrooms and DMT, are on the top and left, and your more dangerous drugs, like opioids and benzos, are on the bottom and right.
Trace the columns and rows to find information on how safe, when combined, the drugs are. That’s 600 different interactions.
In the upper right corner of this chart is the key. Yellow squares warrant caution. Orange squares mean the combination is unsafe. Red squares mean it’s downright dangerous.
For example, mixing cocaine with alcohol is unsafe. Mixing opioids with benzos (for example, heroin with klonopin) is dangerous.
To see what, exactly, the negative effects can be, check out the individual drug entries on TripSit. They made the chart. A few other organizations, like DanceSafe can help you figure out what’s really in your molly and which drug combos are dangerous.
But this chart has a fascinating twist. Your DARE officer is going to hate this, but this chart doesn’t just show you what’s dangerous — it shows you what might be awesome.
The dark green squares show which drugs combination boost each other, while also being low-risk. These are “synergistic” combinations, i.e., heightening, while still posing a low risk to your physical health.
It’s mostly the natural, hippie drugs, like DMT and mushrooms, that are low-risk, and low-risk when combined. So LSD plus MDMA (“candyflipping”)- for example, is a music festival highlight, and listed here as “synergistic and low-risk.”
Low risk means physical low risk. High doses in the wrong situations, of course — like with strangers, or in public, in jail or on a bicycle — can wreck your head and ruin lives.
But there are 145 drug combinations listed as synergist and low-risk. That’s 145 fascinating and illuminating and relatively safe ways to flunk out of school. One hundred forty five psychologically traumatizing ways to pass a 10-hour workplace seminar.
And, maybe, 145 astonishing ways to change your life.
That’s because some of these combinations are known to be more than just excellent fun. For example, as the chart shows, when you take an antidepressant called an MAOI and ingest the natural psychedelic DMT, it’s not only synergistic and low risk, it’s called ayahuasca, and it can cure depression, drug addiction and acedia.
This chart has another interesting feature. It shows which drug combinations are merely boring. The light green squares show which combos are low risk but don’t add anything to the other. And the blue squares show drug combos are also low risk, but where each effects blunt the other. So alcohol, despite its wide use, actually dampens the effects of things like mushrooms or mescaline.
Caveat tripper, of course. This chart is mostly crowdsourced; it’s based on what trippers say happened to them; there aren’t many placebo-controlled, double-blind scientific studies here. Actual results may melt your face.
Also, the chart is extremely limited. It doesn’t show most legal drugs, which can be more dangerous than the illegal drugs. Talk to your doctor. (Seriously. Talk to her. She won’t snitch. Mine is extremely cool about this stuff.) And combine all this with the deep resources of Erowid, reddit and Wikipedia. And, please, please, please think real hard before you drink ayahuasca by yourself, or candyflip during a job interview, or hippieflip at the edge of the Grand Canyon.
But marvel at this chart as another amazing thing the Internet has brought us. It’s more proof that outdoor drug dealers can be nearly as responsible as the indoor drug dealers. And it’s more proof that regular drug users are doing work the government tried and failed to do, by showing which drugs, and drug combinations, are actually dangerous and can hurt us, and which drugs, and drug combinations, might actually help people live meaningful, enjoyable and purpose-driven lives.
Go to Article Roster – Click Here
Canadian Researchers: Use Medical Marijuana Instead Of Opioids
Using opiods for pain is a hard thing for many people.
Sure, the painkillers provide temporary relief from pain, but the side effects can be horrific. They tear up your organs, and often times lead to a level of addiction that ruins lives. If only there was another medicine out there that was effective that didn’t come with all of the problems…You see where I’m going with this. Medical marijuana is a proven form of treatment for pain, specifically neuropathic pain.
Recently researchers in Canada started pushing for Canadian doctors to substitute opioid based painkillers for medical marijuana. Per The Globe and Mail:
Canadian doctors should use medical marijuana instead of frequently abused opioids to treat patients with neuropathic pain and a host of other conditions cannabis has been proven to combat, Vancouver-based HIV/AIDS researchers argue in a newly published editorial.
Thomas Kerr, Julio Montaner and Stephanie Lake of the B.C. Centre for Excellence in HIV/AIDS argue the Canadian Medical Association is holding pot to a higher standard than other pain-relieving pharmaceutical drugs and is ignoring high-quality, peer-reviewed studies on the use of cannabis. Their editorial is in the latest edition of the Journal of the Canadian Public Health Association.
Dr. Kerr, co-director of the centre’s Urban Health Research Initiative, said five recent randomized control trials and two systemic reviews have found marijuana helps relieve neuropathic pain. Yet many doctors are still loathe to prescribe a drug that has not been approved by Health Canada.
Doctors should want their patients to get better, and in the meantime reduce their suffering. Getting patients hooked on pharmaceutical painkillers may reduce their suffering for a brief time, but it rarely results in patients getting better. As I said earlier, it often times ruins the person’s life with addiction and the creation of other ailments due to the side effects of the painkillers. Marijuana is medicine, proven by science, and it’s a much, much better alternative to pharmaceutical painkillers. It’s time that doctors in Canada, and around the world, got on board. People’s lives are depending on it.
See Story in – The Globe and Mail
IACM: Nomination of IACM Ambassadors
In order to establish a wider network that will work together toward its aims as mentioned in the statutes, the IACM has nominated ambassadors in different countries around the world. There are both Professional Ambassadors and Patient Ambassadors, as well as Partner Organizations
The list of ambassadors is as follows:
Alex Mabou Tagne (Cameroon)
Daniela Parolaro (Italy)
Donald Abrams (USA)
Ethan Russo (USA)
Francesco Crestani (Italy)
Franjo Grotenhermen (Germany)
Gastone Zanette (Italy)
Gianpaolo Grassi (Italy)
Ilya Reznik (Israel)
Kirsten Müller-Vahl (Germany)
Manuel Guzman (Spain)
Mark Ware (Canada)
Marlon Germon (South Africa)
Marry Lynn Mathre (USA)
Natalie Krapivensky (Australia)
Raquel Peyraube (Uruguay)
Roger Pertwee (UK)
Rudolf Brenneisen (Switzerland)
Steve Goldner (USA)
Alison Myrden (Canada)
Carola Pérez Gómez (Spain)
Hana Vágnerová (Czech Republic)
Marian Hutten (Netherlands)
Max Plenert (Germany)
Michael Krawitz (USA)
Sarah Martin (UK)
Sébastien Béguerie (France)
For more details about the ambassadorship program, you may contact our Partnership and Network Coordinator Yuval Zolotov at [email protected]
Science/Human: Legalization of cannabis for medical use in the US is associated with reduced opioid prescriptions
“Statewide medical cannabis legalization appears to have been associated with reductions in both prescriptions and dosages of Schedule III (but not Schedule II) opioids received by Medicaid enrollees in the US,” scientists from the Department of Family Medicine and Public Health of the University of California in San Diego, USA, wrote. They analysed state-level opioid prescription records from 1993 to 2014 of data from Medicaid. Medicaid is a program that helps with medical costs for some people with limited income and resources.
For Schedule III opioid prescriptions, medical cannabis legalization was associated with a 29.6% reduction in number of prescriptions, 29.9% reduction in dosage, and 28.8% reduction in related Medicaid spending. No evidence was found to support the associations between medical cannabis legalization and Schedule II opioid prescriptions Authors estimated that, if “all the states had legalized medical cannabis by 2014, Medicaid annual spending on opioid prescriptions would be reduced by 17.8 million dollars.” Schedule II opioids are morphine, fentanyl and others. Schedule III opioids are buprenorphine, tramadol and others.
Liang D, Bao Y, Wallace M, Grant I, Shi Y. Medical Cannabis Legalization and Opioid Prescriptions: Evidence on US Medicaid Enrollees during 1993-2014. Addiction. 2018 Jul 10. [in press]
Science/Human: Cannabis use is associated with decreased mortality in hospital after a heart attack
In a study with 1,273,897 patients with acute myocardial infarctions cannabis use was associated with decreased in-hospital deaths. Furthermore, cannabis use was not associated with increased risk of adverse short-term outcomes following a heart attack. In total 3854 patients reported cannabis use. Researchers of the Division of Cardiology of the University of Colorado Anschutz in Aurora, USA, analysed hospital records from 8 states between 1994 and 2013.
Cannabis users were more likely to be placed on mechanical ventilation (odds ratio 1.19). They were significantly less likely to die (OR 0.79), experience shock (OR 0.74) or require an intra-aortic balloon pump (OR 0.80) after acute myocardial infraction (AMI) than patients with no reported cannabis use. Authors wrote that these “results suggest that, contrary to our hypothesis, marijuana use was not associated with increased risk of adverse short-term outcomes following AMI. Furthermore, marijuana use was associated with decreased in-hospital mortality post-AMI.”
Johnson-Sasso CP, Tompkins C, Kao DP, Walker LA. Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction. PLoS One. 2018;13(7):e0199705.
Science/Human: CBD reduces seizures in several further childhood-onset epilepsy forms according to an open-label study
In an open study with 46 patients with CDKL5 deficiency disorder or Aicardi, Doose, and Dup15q syndromes a treatment with CBD reduced the frequency of convulsive seizures. Investigators of New York University School of Medicine, USA, included patients aged 1-30 years with these severe childhood-onset epilepsy forms. They were treated with CBD for at least 10 weeks.
The percent change in median convulsive seizure frequency for all patients taking CBD decreased from baseline to week 12 by 51.4% and week 48 by 59.1%. CBD was generally well tolerated. Authors wrote that the study “provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy” associated with these disorders.
Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 Jul 10. [in press]
News in brief
Lebanon: Parliament considers cultivation of cannabis for medical use
Lebanon’s parliament is considering legalizing the cultivation of cannabis for medical purposes, Parliament Speaker Nabih Berri said on 18 July. Although growing the plant is illegal in Lebanon, landowners nevertheless have for decades openly grown cannabis in the fertile Bekaa Valley.
Reuters of 18 July 2018
Science/Human: Legalisation of cannabis in some US states is associated with improvement in some clearance rates by the police
Scientists assessed crime clearance rates in Colorado and Washington before and after the enactment of cannabis legalization for recreational use. Their findings suggest no negative effects of legalization on crime clearance rates. “Our findings suggest legalization has resulted in improvements in some clearance rates,” they wrote.
Department of Criminal Justice and Criminology, Washington State University, Pullman, USA.
Makin DA, et al. Police Quarterly. 2018 Jul 4. [in press]
Science/Animal: Endocannabinoids produced from omega-3 fatty acids have anti-cancer effects
The intake of omega-3 fatty acids increased the production of endocannabinoid substances (DHEA, EDP-EA) with anti-cancer effects in osteosarcoma, a bone cancer, by several mechanisms, including reduction of tumour growth, metastasis and the production of new blood vessels in the tumour. These effects were partially mediated through the cannabis receptor 1.
University of Illinois, Urbana, USA.
Science Daily of 13 July 2018
Roy J, et al. J Med Chem. 2018;61(13):5569-5579.
Science/Human: Large variation of plasma concentrations of THC and CBD after oral intake
In a study with 12 multiple sclerosis patients, who received 2 sprays of the cannabis extract Sativex containing 2.7 mg THC and 2.5 mg CBD in 1 spray, maximum concentrations in blood plasma varied considerably. Maximum THC plasma levels varied from 0.60 to 13.29 ng/mL and CBD plasma levels range from 0.55 to 11.93 ng/mL. Time to peak plasma concentrations ranged from 150 to 240 minutes for THC and 90 to 240 minutes for CBD.
IRCCS, Institute of Neurological Sciences, Bologna, Italy.
Contin M, et al. Clin Neuropharmacol. 2018 Jul 18. [in press]
Science/Cells: CBD may be effective in several breast cancer types
CBD induces apoptosis (programmed cell death) in several breast cancer cells, including ER -positive and triple negative breast cancer cells.
Department of Biochemistry, Faculty of Science, Alexandria University, Egypt.
Sultan AS, et al. 2018;41:34-41.
Science/Human: CBD was effective in several epilepsy forms in the long-term
In a long-term observational study with 607 patients treated at 25 sites in the US with CBD up to a maximum dose of 25 to 50 mg/kg bodyweight treatment effects after 96 weeks were similar to those after 12 weeks.
University of Alabama, Birmingham, USA.
Szaflarski JP, et al. Epilepsia. 2018 Jul 12. [in press]
Science/Human: The effect of cannabis on insomnia depended on the cannabis variety
In a study with 409 people with a specified condition of insomnia CBD was associated with greater symptom relief than THC. Flowers from sativa subtypes were associated with more negative side-effects than flowers from indica or hybrid plant subtypes.
Department of Psychology, University of New Mexico, Albuquerque, USA.
Vigil JM, et al. Medicines (Basel). 2018;5(3).
Science/Human: Pain patients who use cannabis have greater pain severity than non-users
According to a survey with 1514 pain patients contacted by phone cannabis use was associated with a greater pain severity score compared to non-users. Authors wrote that there “was no evidence that cannabis use reduced pain severity or interference or exerted an opioid-sparing effect.” However, it may also be possible, that patients with more severe pain are more likely to use cannabis.
National Drug and Alcohol Research Centre, Sydney, Australia.
Campbell G, et al. Lancet Public Health. 2018;3(7):e341-e350.
Science/Cells: Cannabis compounds interact synergistically for anti-cancer activity against colon cancer
Colon cancer cells were exposed to several ethanol extracts from cannabis. Researchers found that some cannabis compounds acted synergistically to produce toxic effects on these cancer cells, induce cell cycle arrest and apoptosis (programmed cell death). Among these compounds is cannabigerolic acid.
Agricultural Research Organization, Volcani Center, Bet Dagan, Israel.
Nallathambi R, et al. Cannabis Cannabinoid Res. 2018;3(1):120-135.
Science/Animal: A mechanism of action of CBD’s antidepressant effects
Researchers investigated the effects of CBD on a certain brain region (hippocampus) of mice. They wrote that the investigation suggests “that the hippocampal BDNF-TrkB-mTOR pathway is vital for cannabidiol-induced antidepressant-like effect.”
Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil.
Sartim AG, et al. J Psychopharmacol. 2018:269881118784877.
Science/Human: Cannabis may have therapeutic effects in patients with sickle cell disease
An analysis of 44 patients, who received cannabis for medical reasons, showed that cannabis products may be beneficial in this patient group.
Yale Cancer Center, Yale University, New Haven, USA.
Roberts JD, et al. Cannabis Cannabinoid Res. 2018;3(1):162-165.
Science/Human: CBD is mostly used against pain, sleep disorders, anxiety and depression
In an online survey with 2409 participants recruited through social media almost 62% of CBD users reported using the cannabinoid to treat a medical condition. The top medical conditions were pain, sleep disorders, anxiety, and depression. Almost 36% of respondents reported that CBD treats their medical condition “very well.”
The Center for Medical Cannabis Education, Del Mar, USA.
Corroon J and Phillips JA.Cannabis Cannabinoid Res. 2018;3(1):152-161.
Science/Human: Cannabis users need higher doses of opioids after surgery
In an analysis of 434 patients, who underwent weight reduction surgeries, those with cannabis use (36 patients) need higher doses of opioids. Authors assume that this is due to the development of cross tolerance.
Saint Joseph Hospital, Denver, USA.
Bauer FL, et al. Perm J. 2018;22.
Science/Cells: Cannabigerol has anti-inflammatory and neuroprotective properties
The plant cannabinoid cannabigerol (CBG) protected nerve cells against the toxicity induced by stimulated macrophages. It counteracted the production of pro-inflammatory messengers.
IRCCS Centro Neurolesi “Bonino Pulejo”, Messina, Italy.
Gugliandolo A, et al. J Mol Sci. 2018;19(7).
Science/Animal: Activation of the peripheral CB1 receptor may be beneficial in chemotherapy-induced peripheral neuropathy
In a study with rats with cisplatin-induced peripheral neuropathy the administration of a synthetic cannabinoid, which does not penetrate into the brain, suppressed allodynia. Allodynia refers to a pain sensation from a stimulus (e.g. touch, cold), which usually does not cause pain.
Laboratory of Neuropharmacology, University of California, Los Angeles, USA.
Mulpuri Y, et al. Neuropharmacology. 2018;139:85-97.
Science/Cells: Activation of the CB2 receptor decreases viability of leukaemia cells
A new synthetic cannabinoid with high affinity to the CB2 receptor inhibits cell survival in leukaemia cells, but it did not damage normal healthy lymphocytes.
Department of Experimental Medicine, University of Rome “La Sapienza”, Italy.
Capozzi A, et al. Int J Mol Sci. 2018;19(7).
A glimpse @ the past
One year ago
- Science/Human: The use of cannabis improves performance during simulated night shift work
- Science/Human: Cannabis may be helpful in restless legs syndrome according to case reports
- Uruguay: Pharmacies have begun to sell cannabis
Two years ago
Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
– Reynolds – 2018 – Evolution Letters – Wiley Online Library
Secondary metabolites are a heterogeneous class of chemicals that often mediate interactions between species. The tryptophan‐derived secondary metabolite, psilocin, is a serotonin receptor agonist that induces altered states of consciousness. A phylogenetically disjunct group of mushroom‐forming fungi in the Agaricales produce the psilocin prodrug, psilocybin. Spotty phylogenetic distributions of fungal compounds are sometimes explained by horizontal transfer of metabolic gene clusters among unrelated fungi with overlapping niches. We report the discovery of a psilocybin gene cluster in three hallucinogenic mushroom genomes, and evidence for its horizontal transfer between fungal lineages. Patterns of gene distribution and transmission suggest that synthesis of psilocybin may have provided a fitness advantage in the dung and late wood‐decay fungal niches, which may serve as reservoirs of fungal indole‐based metabolites that alter behavior of mycophagous and wood‐eating invertebrates. These hallucinogenic mushroom genomes will serve as models in neurochemical ecology, advancing the (bio)prospecting and synthetic biology of novel neuropharmaceuticals.
See Story here – Wiley Online Library
Psychedelics Promote Structural and Functional Neural Plasticity
Neuropsychiatric diseases, including mood and anxiety disorders, are some of the leading causes of disability worldwide and place an enormous economic burden on society (Gustavsson et al., 2011, Whiteford et al., 2013). Approximately one-third of patients will not respond to current antidepressant drugs, and those who do will usually require at least 2–4 weeks of treatment before they experience any beneficial effects (Rush et al., 2006). Depression, post-traumatic stress disorder (PTSD), and addiction share common neural circuitry (Arnsten, 2009, Russo et al., 2009, Peters et al., 2010, Russo and Nestler, 2013) and have high comorbidity (Kelly and Daley, 2013). A preponderance of evidence from a combination of human imaging, postmortem studies, and animal models suggests that atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders and is precipitated and/or exacerbated by stress (Arnsten, 2009, Autry and Monteggia, 2012, Christoffel et al., 2011, Duman and Aghajanian, 2012, Duman et al., 2016, Izquierdo et al., 2006, Pittenger and Duman, 2008, Qiao et al., 2016, Russo and Nestler, 2013). These structural changes, such as the retraction of neurites, loss of dendritic spines, and elimination of synapses, can potentially be counteracted by compounds capable of promoting structural and functional neural plasticity in the PFC (Castrén and Antila, 2017, Cramer et al., 2011, Duman, 2002, Hayley and Litteljohn, 2013, Kolb and Muhammad, 2014, Krystal et al., 2009, Mathew et al., 2008), providing a general solution to treating all of these related diseases. However, only a relatively small number of compounds capable of promoting plasticity in the PFC have been identified so far, each with significant drawbacks (Castrén and Antila, 2017). Of these, the dissociative anesthetic ketamine has shown the most promise, revitalizing the field of molecular psychiatry in recent years.
Ketamine has demonstrated remarkable clinical potential as a fast-acting antidepressant (Berman et al., 2000, Ionescu et al., 2016, Zarate et al., 2012), even exhibiting efficacy in treatment-resistant populations (DiazGranados et al., 2010, Murrough et al., 2013, Zarate et al., 2006). Additionally, it has shown promise for treating PTSD (Feder et al., 2014) and heroin addiction (Krupitsky et al., 2002). Animal models suggest that its therapeutic effects stem from its ability to promote the growth of dendritic spines, increase the synthesis of synaptic proteins, and strengthen synaptic responses (Autry et al., 2011, Browne and Lucki, 2013, Li et al., 2010).
Like ketamine, serotonergic psychedelics and entactogens have demonstrated rapid and long-lasting antidepressant and anxiolytic effects in the clinic after a single dose (Bouso et al., 2008, Carhart-Harris and Goodwin, 2017, Grob et al., 2011, Mithoefer et al., 2013, Mithoefer et al., 2016, Nichols et al., 2017, Sanches et al., 2016, Osório et al., 2015), including in treatment-resistant populations (Carhart-Harris et al., 2016, Carhart-Harris et al., 2017, Mithoefer et al., 2011, Oehen et al., 2013, Rucker et al., 2016). In fact, there have been numerous clinical trials in the past 30 years examining the therapeutic effects of these drugs (Dos Santos et al., 2016), with 3,4-methylenedioxymethamphetamine (MDMA) recently receiving the “breakthrough therapy” designation by the Food and Drug Administration for treating PTSD. Furthermore, classical psychedelics and entactogens produce antidepressant and anxiolytic responses in rodent behavioral tests, such as the forced swim test (Cameron et al., 2018) and fear extinction learning (Cameron et al., 2018, Catlow et al., 2013, Young et al., 2015), paradigms for which ketamine has also been shown to be effective (Autry et al., 2011, Girgenti et al., 2017, Li et al., 2010). Despite the promising antidepressant, anxiolytic, and anti-addictive properties of serotonergic psychedelics, their therapeutic mechanism of action remains poorly understood, and concerns about safety have severely limited their clinical usefulness.
Because of the similarities between classical serotonergic psychedelics and ketamine in both preclinical models and clinical studies, we reasoned that their therapeutic effects might result from a shared ability to promote structural and functional neural plasticity in cortical neurons. Here, we report that serotonergic psychedelics and entactogens from a variety of chemical classes (e.g., amphetamine, tryptamine, and ergoline) display plasticity-promoting properties comparable to or greater than ketamine. Like ketamine, these compounds stimulate structural plasticity by activating the mammalian target of rapamycin (mTOR). To classify the growing number of compounds capable of rapidly promoting induced plasticity (Castrén and Antila, 2017), we introduce the term “psychoplastogen,” from the Greek roots psych- (mind), -plast (molded), and -gen (producing). Our work strengthens the growing body of literature indicating that psychoplastogens capable of promoting plasticity in the PFC might have value as fast-acting antidepressants and anxiolytics with efficacy in treatment-resistant populations and suggests that it may be possible to use classical psychedelics as lead structures for identifying safer alternatives.
Because atrophy of cortical neurons is believed to be a contributing factor to the development of mood and anxiety disorders (Christoffel et al., 2011, Duman and Aghajanian, 2012), we first treated cultured cortical neurons with psychedelics from a variety of structural classes (Figures 1A and S1A) and measured the resulting changes in various morphological features. Using Sholl analysis (Ristanović et al., 2006), we observed that several psychedelics increased dendritic arbor complexity comparably to ketamine, as measured by the area under the curve of the Sholl plots as well as the maximum number of crossings (Figures 1B–1E and S1B–S1E). This increase in arbor complexity appeared to result from large changes in both the number of dendritic branches and the total length of the arbors (Figures 1F, 1H, S1F, and S1H). Psychedelics had a limited effect on the number of primary dendrites and did not alter the length of the longest dendrite (Figures 1G, 1I, S1G, and S1I).
Nearly all psychedelic compounds tested were capable of robustly promoting neuritogenesis, with comparable effects being produced by tryptamines (N,N-dimethyltryptamine [DMT] and psilocin), amphetamines (2,5-dimethoxy-4-iodoamphetamine [DOI] and MDMA), and ergolines (lysergic acid diethylamide [LSD]). As a positive control, we treated cells with 7,8-dihydroxyflavone (DHF), a psychoplastogen structurally dissimilar to classical psychedelics (Jang et al., 2010), and found that it also increased dendritic arbor complexity (Figure S2). This neurite outgrowth structural phenotype seems to only be induced by select compounds because serotonin and D-amphetamine, molecules that are chemically related to classical psychedelics and entactogens, exerted minimal to no effects on neuritogenesis (Figure S2).
To establish the relative potencies and efficacies of hallucinogens and entactogens for promoting neurite outgrowth, we conducted 8-point dose-response studies (Figure S3). We defined 100% and 0% efficacy as the maximum number of crossings induced by ketamine (10 μM) and vehicle (0.1% DMSO), respectively. We chose the 10 μM concentration of ketamine as the upper limit because this concentration of ketamine is reached in the brain following intraperitoneal administration of an antidepressant dose in rats (Yang et al., 2018). For consistency, we used this same concentration when testing the effects of psychedelics and entactogens, with DMT being the only exception. We used a maximum 90 μM concentration of DMT in our studies to more closely mimic the brain concentration of DMT in rats treated with an antidepressant dose (Cohen and Vogel, 1972, Cameron et al., 2018). In this neuritogenesis assay, ketamine’s half maximal effective concentration (EC50) value was 132 nM. Surprisingly, the majority of the psychedelics and entactogens we tested exhibited significantly greater potency than ketamine, with LSD being particularly potent (EC50 = 0.409 nM). In fact, LSD exhibited activity across 8 orders of magnitude into the low picomolar range (Figure S3).
Notably, the anti-addictive alkaloid ibogaine (Alper, 2001, Belgers et al., 2016) was the only psychedelic tested that had absolutely no effect (Figure S4). This was a surprising result because we hypothesized that ibogaine’s long-lasting anti-addictive properties might result from its psychoplastogenic properties. Previous work by He et al. (2005) clearly demonstrated that ibogaine increases the expression of glial cell line-derived neurotrophic factor (GDNF) and that this plasticity-promoting protein is critical to ibogaine’s anti-addictive mechanism of action. Because several reports have suggested that noribogaine, a metabolite of ibogaine, might actually be the active compound in vivo (Zubaran et al., 1999, Baumann et al., 2000, Baumann et al., 2001), we decided to test its ability to promote neuritogenesis in cultured cortical neurons. Gratifyingly, noribogaine robustly increased dendritic arbor complexity with an EC50 value comparable to ketamine (Figure S3), providing additional evidence suggesting that it may be the active compound in vivo.
To assess the in vivo effects of classical psychedelics on neuritogenesis, we started treating Drosophila larvae during the first instar with LSD and DOI. As observed in rodent cortical cultures, both LSD and DOI significantly increased dendritic branching of class I sensory neurons; however, they did not increase the total length of the dendritic arbors (Figures 1J–1L). Because of the striking effects of psychedelics on the structures of immature neurons, we hypothesized that they might influence neurodevelopment. To test this, we chronically treated zebrafish embryos with compounds for 6 days immediately following dechorionation and assessed gross morphological changes and behavior. We did not observe any differences in head sizes between the treatment groups, nor did we detect any statistically significant differences in activity levels (Figure S5). Next we assessed the ability of psychedelics to promote neuritogenesis in more mature neurons by starting to treat Drosophila larvae during the late second instar. Again, psychedelics increased the branching of class I neurons, although the effect was less dramatic than that observed when treatment was started during the first instar (Figure 1M–1O). Although different developmental stages might be more or less susceptible to the effects of psychedelics, it is also possible that the smaller effect size observed after administering compounds starting at the later time point was simply the result of treating the larvae for a shorter period of time. Regardless, it was quite surprising to observe compound-induced changes in neuronal structure after initiating treatment during the late second instar because class I neurons are stereotyped and typically possess relatively few higher-order branches (Grueber et al., 2002). Moreover, our results demonstrate that psychedelics can promote changes in neuronal structure across vertebrate (rats) and invertebrate (Drosophila) species, suggesting that they act through an evolutionarily conserved mechanism.
Information can be found here – Psychedelics Promote Structural and Functional Neural Plasticity
Research on psychedelics makes a comeback
Forty years after federal laws criminalized the use of psychedelics for non-medical purposes in FDA-regulated psychological and drug research, the study of these drugs is picking up again, and their use in treating certain patients shows promise. Researchers are finding that the drugs may help improve functioning and lift the spirits of those with cancer and other terminal diseases, as well help treat people with post-traumatic stress disorder.
In a pilot study published online in September and slated to appear in the January 2011 Archives of General Psychiatry (Vol. 68, No. 1), University of California, Los Angeles, researchers led by Charles Grob, MD, showed that a modest dose of psilocybin — the active ingredient in “magic mushrooms” — given to terminal cancer patients under the supervision of trained therapists helped ease anxiety and improve mood for up to six months. In addition to feeling calmer and happier, researchers say, the participants reported forging a closer connection to friends and family members.
These types of research studies have continued to point to the possibility that the benefits of these illegal drugs may outweigh the risks in certain scenarios. As a result, the FDA and the Drug Enforcement Administration have eased regulations and also given approval to researchers at Johns Hopkins University and New York University’s Langone Medical Center to study the use of psilocybin to treat death anxiety among cancer patients.
Several other small-scale studies have also shown success in using another mind-altering drug — MDMA, often referred to as ecstasy — in conjunction with psychotherapy to treat PTSD. In a study with 20 patients published online in July in the Journal of Psychopharmacology, South Carolina-based psychiatrist Michael Mithoefer, MD, and colleagues provided two eight-hour psychotherapy sessions to patients, half of whom received a dose of MDMA during the sessions and the other half a placebo. Two months after the last session, researchers found that more than 80 percent of the trial group no longer met diagnostic criteria for PTSD, compared with only 25 percent of the control group. Mithoefer is now recruiting subjects for a pilot study of PTSD treatment among veterans.
In all of these studies, the goal was to help patients reduce their fears, says Thomas Roberts, PhD, an educational psychologist at Northern Illinois University and co-editor of “Psychedelic Medicine” (Praeger, 2007). “It is more psychotherapeutic than biological or neurological,” he says.
It’s important to note, researchers say, that psychedelic drugs can elicit fear, anxiety or paranoia, depending on the dose provided and an individual’s personality. Therefore, this research is done only in a carefully controlled setting and under the care of a trained therapist.
Rick Doblin, PhD, executive director of the Multidisciplinary Association of Psychedelic Studies, a California-based nonprofit organization that is funding several of these studies, says psychologists will be increasingly tapped to conduct this research and explore the ramifications of the use of psychedelics.
“Considering how important improving end-of-life care has become in our society, as evidenced by the rise of the hospice movement, I think it’s likely that this field will continue to expand and become more relevant,” Doblin says.
P.W. Barber is the author of Psychedelic Revolutionaries: LSD and the Birth of Hallucinogenic Research.
Somewhere, a Cheshire Cat is smiling.
If you’ve been paying attention to the health news of late, you might think you’ve have travelled back in time to the 1960s. It’s not a bad acid trip. We are in the midst of a “renaissance” in psychedelic science, as the author Michael Pollan called it last month in the pages of The New York Times. Researchers are examining the potential of drugs like LSD and psilocybin (“magic mushrooms”) – recreational drugs mostly associated with the 1960s counterculture – to act as psycho-therapeutic tools in the treatment of severe addictions, end-of-life anxiety, depression, and post-traumatic stress disorder. We’re high on getting high.
Truth be told, many of the new findings are in fact old discoveries from the 1950s and 60s – dusted off and updated for the 21st century. Uncovering this revolutionary past has much to offer to the movement that is presently unfolding in Canada and abroad.
When classic psychedelics, particularly lysergic acid diethylamide (LSD), were legally banned, and restrictions against their use put in place, in the late 1960s and 70s, the widely held opinion in the psychiatric and scientific communities – and, at least among non-users, society at large – was that they were too dangerous. Psychedelics, many argued, had the potential for serious abuse. Furthermore, claims of their medical value were overinflated and lacking a firm evidence base. Not surprisingly, this resulted in a halt to scientific research in the area – although recreational use continued.
Psychedelic science’s demise has become the subject of a growing body of historical analyses over the last decade, many of which point to, as contributing factors, a convoluted mixture of 1960s countercultural excesses (that is, psychedelic gurus and the LSD social movement), transformations in psychiatry (and how mental illnesses are understood, diagnosed and treated as well as what constitutes acceptable clinical research methodology), and even the covert experimentation of the U.S. Central Intelligence Agency (CIA).
After several decades of being in cryogenic stasis, experimental research with psychedelics is back and attracting the attention of those in and outside of the scientific community. Leading the charge is a new generation of researchers, based out of centres such as Johns Hopkins University, New York University and Britain’s Imperial College in London, whose findings hold promise in treating mental illness.
Attitudes toward recreational drugs are shifting in North America, with legalization of recreational marijuana increasingly prevalent in the United States, and, come Oct. 17, across Canada. Could magic mushrooms be next?
Perhaps no one definitive answer exists to answer the question of why we’re in the midst of this so-called renaissance in psychedelic science. Certainly, many have alluded to mental health and addictions systems being in crisis.
Gauging by the staggering human and financial costs associated with mental health and addictions, plus the fact that demand for services and treatment appear to be outpacing the supply, it is easy to see why there is concern.
Roughly one in five people in Canada experience a mental illness in their lifetime. According to CAMH, Canada’s premier research and treatment centre for mental health and addictions, 6.7 million Canadians suffer from mental illness, the cost of which is estimated to be $51-billion a year when factoring in health-care costs, lost productivity and reductions in health-related quality of life.
In the United States, recent data indicate that more than 43 million Americans suffer from a mental-health disorder and close to half of that number have a co-occurring substance-abuse disorder. Approximately 9.6 million Americans have been found to experience suicidal ideation. In terms of economic costs, the U.S. Substance Abuse and Mental Health Services Administration estimated the costs of mental illness to be a whopping US$467-billion in 2012.
In one area alone – that of PTSD among returning U.S. veterans of the Iraq and Afghanistan wars – the costs are alarming, with one in five veterans (300,000) diagnosed with the disorder. As revealed by some PTSD figures from the same year, first-year treatment cost the government US$8,300 a person, for a total of more than US$2-billion. To add to this, suicides among active-duty military personnel averaged one a day, 20 per cent of all suicides in the United States.
U.S. research has also revealed another troubling statistic: Americans with serious mental illnesses on average die 15 to 30 years earlier than those without, largely owing to the fact that the former have far higher rates of chronic diseases such as cancer, heart disease, stroke, diabetes and respiratory problems (interestingly, the study does not address what, if any, role the current medications used to treat severe mental illness may have had in contributing to these chronic diseases).
There’s no question: We need to do more – and better.
Drugs, of course, have come to occupy an ever growing role in mental-health systems. From the early years of the psychopharmacological revolution in the 1950s onward, we have seen a proliferation in the number of drugs used to treat psychiatric disorders, with numerous variations of anxiolytics, antidepressants, anti-psychotics and other psychotropic medications. Whether these drugs, and the theories that go with them, have been a help or hindrance in the battle against mental illness continues to be a source of heated debate.
In an interview with The Canadian Press earlier this year, University of Saskatchewan medical historian Erika Dyck speculated the revival of scientific interest in these taboo drugs might have to do with people’s desperation to find a therapy that works.
Most professionals working in the field will admit the standard medications being used to treat severe mental illnesses and addictions have their obvious benefits, but they also come with significant limitations; at best, the drugs have proven to be effective in the management of symptoms, and for some patients more than others. Unfortunately, the drugs have not been nearly as effective in treating the underlying illness.
In a recent episode of CBC Radio’s White Coat, Black Art, Brian Goldman profiles the burgeoning use of these drugs and just how difficult it is for some people to stop taking them. Citing data from a New York Times article, Dr. Goldman noted that from 2013 to 2014, 34.4 million adults were taking antidepressants, an increase of 250 per cent from a survey completed in 1999 to 2000. Canada also happens to be one of the largest consumers of antidepressants, ranking third on an Organization for Economic Co-operation and Development list of industrialized countries.
More problematic is the fact many of those taking antidepressants are long-term users who face the difficult challenge of withdrawal when attempting to discontinue the medications.
Along with psychopharmaceuticals such as anti-depressants, opioids are another burgeoning area of drug use – and abuse – in North America. Commonly used for pain management or to treat addictions, they are now associated primarily with a crisis that dominates today’s news headlines. Psychedelics may have a hand to play here as well. In the 1990s, Russian researchers Krupitsky et al. employed the Saskatchewan psychedelic therapeutic model, using “high dose” ketamine to successfully treat heroin addiction. And today, there continues to be discussion around the potential of other psychedelics (such as ibogaine and ayahuasca) to achieve lasting abstinence from opioid addiction, with some addicts turning to psychedelic therapy as an alternative to opiate replacement drugs such as methadone and suboxone.
In Canada, opioid-related overdoses now account for more deaths than automobile accidents; this week, the Special Advisory Committee on the Epidemic of Opioid Overdoses released data revealing that almost 4,000 Canadians died as a result of opioids last year – with over 90 per cent of these deaths being ruled as accidental or unintentional – a staggering 34 per cent increase from 2016. (One of the more disconcerting stories to have appeared in recent years has been how some pharmaceutical companies intentionally underplayed the highly addictive nature of their drugs so as to not interfere with marketing efforts and profits.)
Number of apparent opioid-related deaths in Canada by manner of death, 2016 and 2017
Given these scenarios, it begs the question of whether adding psychedelics, whose safety and medical value are still contested, to the mix is a good idea. Granted, the notion that powerful mind-altering substances such as psilocybin might in some way help to alleviate the mental-health and addictions crisis might strike some as ridiculous, unethical or just plain scientifically unsound. Yet, we are once again at a point in time where which these drugs are receiving serious scientific consideration.
New developments on the medical and recreational cannabis front have definitely helped to open the door to other possibilities in psychedelic science. In Canada and many parts of the United States, we have taken an almost 180-degree turn from the era of “reefer madness” to today, when marijuana is being touted for its medical and other benefits.
A group of Canadian psychologists that recently carried out a literature review on medicinal and recreational cannabis pointed to the effectiveness of the drug in treating various ailments, most notably the symptoms related to PTSD. Interestingly, the review also reported on findings from American states where a rise in cannabis, used legally for harm reduction, has correlated with a decrease in opioid overdoses. And just a couple of weeks ago, this newspaper reported on national research that indicated people suffering from PTSD but not medicating with cannabis are far more at risk for depression and suicidal ideation than those who do use cannabis; also referenced were the country’s first randomized controlled trials to assess the usefulness of the drug in treating the disabling disorder.
In the foundational years of psychopharmacology, hallucinogenic drugs such as mescaline and LSD were an integral part of psychiatric research, initially for their ability to produce model psychoses in healthy subjects and then as adjuncts in the psychotherapeutic treatment of various mental ailments and substance-abuse disorders.
One of the more interesting, and one might argue revolutionary, case studies to emerge in the history of psychedelic science was that of Saskatchewan’s research program, which lasted from 1951 until 1961.
During the 1950s, the province was on the cutting edge of mental-health research. Its work with psychedelic drugs in particular spawned numerous theories and novel approaches to psychiatric treatment, creating a situation that led psychopharmacologist David Healy to remark that “Weyburn and Regina were almost as important lights in the psychopharmacological firmament as Paris and Basel.”
In the 1950s, Saskatchewan was one of the first places to conduct human experiments with LSD, assessing its physiological, biochemical and psychological effects and, in the process, mapping out the unknown territories of the “other world.” The Saskatchewan research, in fact, was responsible for the first, and perhaps only, Handbook on the Therapeutic Use of LSD; it fostered a radically innovative mental-hospital design based upon the drug experience; and yes, it will also go down in history for originating the term psychedelic (“mind manifesting”), which psychiatrist Humphry Osmond coined in 1956. Among the major highlights of the research, however, were the accomplishments in the areas of schizophrenia and alcoholism.
At a time when Freudian/psychoanalytical thought dominated psychiatry and theories surrounding schizophrenia, the Saskatchewan researchers, under the direction of the psychiatric duo of Dr. Osmond and Abram Hoffer, led the way in the turn toward biological psychiatry.
As with other researchers of hallucinogens in the 1950s, Saskatchewan’s psychedelic scientists were initially preoccupied with the psychotomimetic (“madness mimicking”) properties of the drugs and their ability to offer a glimpse into the worldview of patients with schizophrenia and other psychoses. But the province quickly separated itself from the rest of the pack in advancing the first specific biochemical theory for the disease (that is, the adrenalin metabolite hypothesis), which, in turn, led to a unique paradigm for understanding, diagnosing and treating the disease.
Based upon two key observations – that mescaline and adrenalin possessed uncanny structural similarities and that mescaline (and other hallucinogens) produced effects in healthy individuals nearly indistinguishable from symptoms associated with acute schizophrenia – Dr. Hoffer and Dr. Osmond launched a full-scale search for the “Mescaline-like Factor” in the human body, which they presumed to be a result of faulty adrenalin metabolism.
The researchers identified adrenochrome as one potential candidate, synthesizing the first pure samples of the chemical and proving it to possess psychotomimetic properties. Their next step was to begin experimenting with possible treatments that might prevent or cut down on the production of the hypothesized toxic substance. (Dr. Hoffer and Dr. Osmond’s use of massive doses of common vitamins such as niacin and ascorbic acid, and their claims of success in restoring wellness to many patients diagnosed with schizophrenia, became the subject of one of the, if not the biggest, controversies in post-Second World War psychiatry.)
Saskatchewan researchers were also among the first to use hallucinogens as therapeutics and as tools in understanding the human mind in general. With the assistance of psychologist Duncan Blewett, the team under Dr. Hoffer and Dr. Osmond became known for their explorations into the psychedelic applications of the drugs. One of their most noteworthy forays was the co-creation of psychedelic-assisted therapy for the treatment of alcoholism, wherein the drug was administered to patients with the goal of achieving a mystical conversion-type experience.
At its peak, Saskatchewan was one of the only places in the world to incorporate this type of therapeutic option as a standard approach to dealing with alcoholism. The positive outcomes achieved with what were described as “hopeless cases” turned heads, the likes of which included Alcoholics Anonymous co-founder Bill W. and High Priest Timothy Leary.
But the hype surrounding Saskatchewan’s psychedelic research was short-lived. By the time the research concluded in the early 1960s, it was embroiled in a series of controversies and would soon be faced with scientific findings from other research centres that failed to replicate its positive findings. At least this has been the standard narrative regarding this episode in psychedelic science history. A fuller reconstruction of the Saskatchewan story, however, makes for a much more complicated picture. It also reveals a host of myths and misconceptions that have lasted to this day, for example, that the research was inseparable from, and even promoted, LSD’s countercultural manifestations or that it was covertly sponsored by the CIA’s MKUltra program.
By 1970, LSD and other psychedelics had become anathema to mainstream scientific and medical communities, their contributions to psychiatric and psychopharmacological history “flushed down the memory hole.”
Despite psychedelics’ illustrious history and their future promise, not everyone is on board. In a recent article in Harper’s magazine, Nick Richardson takes issue with what he feels Michael Pollan and other surveyors of the renaissance to be saying, essentially that “the drugs are a net good and have been banned for nefarious reasons.” Mr. Richardson expresses discomfort with the idea of psychedelic drugs resulting in mystical experiences and is “wary of placing too much trust in psychedelic revelations.” Not only that, he finds psychedelic therapy “to be a little creepy.” I am sure he is not the only one who feels this way.
But Mr. Richardson tends to view pro-psychedelic statements such as those of Mr. Pollan in the same vein as those of psychedelic pied piper Dr. Leary because of their “believing the dangers of psychedelics to be almost non-existent.” I cannot say with absolute certainty that Mr. Pollan denies the dangers inherent in the use of psychedelics; most of the researchers he interviewed would have stressed the dangers involved in psychedelic pursuits, but that these dangers could be controlled for provided the appropriate “set and setting.”
The point here is that suggestions that psychedelics possess scientific and medical value should not be equated with a call for some psychedelic-fuelled utopia or with an appeal to the youth of the world to “turn on, tune in and drop out.” We have hopefully moved beyond the black-and-white portrayals of the drugs as either the panacea for all that ails humankind or the societal scourge they were made out to be at the height of the LSD mania in the 1960s.
Today’s studies seem to indicate that there was validity to some of the earlier discredited research. Take psychedelic-assisted therapy for alcoholism as one example. In a 2012 meta-analysis of early randomized controlled experiments with LSD and alcoholism, Norwegian researchers Krebs and Johansen revealed that, in spite of methodological inconsistencies and weaknesses, “the effectiveness of a single dose of LSD compares well with the effectiveness of daily naltrexone, acamprosate or disulfiram,” three standard medications used to manage alcohol dependence.
The psychedelic renaissance is still in its early days and many challenges lie on the road ahead. Regulatory hurdles and funding still stand as the biggest barriers to present-day research, although government agencies responsible for the regulation and approval of drugs, such as the U.S. Food and Drug Administration and Health Canada, have displayed more openness to the possibility that psychedelics might afford a “breakthrough” with certain mental illnesses and addictions. As it currently stands, most psychedelic drugs continue to be classed under the most restrictive drug schedules for controlled substances, a decision that was made for mostly political reasons.
It is doubtful the support of the pharmaceutical industry will be forthcoming any time soon, which is not surprising given the fact psychedelics pose a direct threat to its bottom line. In the case of psychedelic-assisted therapy, the drugs are a component, albeit a very important component, of a carefully structured therapeutic matrix that has the potential to achieve results in one to two sessions. (Researchers have shown how a single exposure to psychedelics has produced immediate and lasting improvements in symptoms for the patient that last long after the drug has been metabolized and gone from the body.) For this reason alone, psychedelics would not be very appealing to pharmaceutical companies, whose profits depend on clients taking their products on a daily basis for months and years on end.
Many of the successful studies to date have managed to get around these barriers through the dedication and generous funding of non-profit organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS). One of the most advanced areas of study at this time remains the Phase 3 clinical trials unfolding in Canada, the United States and Israel using MDMA (“ecstasy”)-assisted therapy to treat cases of PTSD.
Further advancement in psychedelic science will depend on many things, but there is reason for optimism. If psychedelics are to find a place in mainstream medicine, progress must occur along a scientific path; it will not occur through some social or quasi-religious psychedelic movement, a fact best summed up in a statement by British psychiatrist Ben Sessa’s statement that “doctors need randomized, double-blind, placebo controlled clinical studies, not anecdotal drug experiences, no matter how convincing they may seem to the users.”
Time will tell if we are in store for a repeat performance of psychedelic science circa 1960s or if the field will advance sufficiently to the point where a new era is upon us.
Can anything – LSD perhaps? – help ‘suicide headaches?’
They’re known as “suicide headaches.” Patients claim the pain from cluster headaches is far worse than anything else human beings typically encounter, including childbirth and gallstones.
Bernard Greenberg, a 76-year-old retired cancer doctor from West Chester, has had “the most painful headaches imaginable” for 15 years. They make him feel as if he has “an ice pick going through my temple to my brain.”
Chris Hannah, 54, started having cluster headaches every day at 48. The Doylestown man describes his as feeling like a “severe electrical storm” with “erratic shards of pain” behind his left eye and from his ear to his jaw.
Yet these headaches have gotten surprisingly little research attention over the last 20 years. Their cause is unknown, and patients have had little choice but to try drugs meant for migraines or other conditions. Some patients have become so frustrated with their options that they have experimented with low doses of hallucinogenic mushrooms, which some claim are more effective than legal drugs.
“These people are in dire need of treatment,” said Stephen Silberstein, director of the Jefferson Headache Center.
William Ratner, a pharmacist who is senior marketing director for migraine and headache for Eli Lilly, said companies have had trouble coming up with good treatments.
“It’s not for lack of trying,” he said. “The science just hasn’t been there to help people in a major way.”
Patient groups have lobbied for more clinical trials of treatments specifically for cluster headaches, and that is finally happening. Local doctors are testing a new monoclonal antibody from Lilly and a wand that stimulates a key nerve through a small implant in a patient’s cheek. Doctors and patients are awaiting the Food and Drug Administration’s decision on another type of electrical stimulation that targets the vagus nerve. A trial that will for the first time scientifically test whether magic mushrooms really do help – no small feat in the risk-averse research world – may start soon.
The question of whether illegal psychedelic drugs can help headache patients has been “radioactive,” said Brian McGeeney, a Boston Medical Center neurologist who thinks the drugs deserve more study.
Sharp, one-sided pain
Cluster headaches are nothing like the tension headaches that almost everyone has experienced. Their intensity has more in common with migraines, but doctors say there are key differences. Migraines are sick headaches. Sufferers – there are more women than men – often feel nauseated and want to lie down in a dark room.
Cluster headaches have sharp, one-sided pain that leaves victims – there are more men than women – feeling “activated, like they want to run around the block or smack their head against the wall,” said John Detre, a Penn Medicine neurologist. Eyes often turn red and water. Noses run. Cluster headaches tend to be shorter than migraines, about 15 minutes to an hour.
They’re called cluster headaches because they tend to come in groups. Most sufferers have “episodic” headaches, or attacks that occur for two to three months out of a year, said William Young, a Jefferson headache specialist. About 20 percent of cluster sufferers have “chronic” headaches that happen every day like Hannah’s.
Estimates of how many people have cluster headaches vary considerably, but doctors say the condition affects about as many Americans as multiple sclerosis, around 400,000.
Patients are often treated with drugs in the triptan family, which can be injected under the skin or inhaled. Inhaling pure oxygen helps shorten some people’s attacks. Each of these helps about 70 percent of patients, said Jason Rosenberg, a headache specialist with Kaiser Permanente of the Mid-Atlantic States. Doctors often put patients in the midst of an attack on a course of high-dose steroids.
“Even the most proven treatments are suboptimal in terms of cost and convenience,” Rosenberg said.
Hannah, who founded the Cluster Headache Support Group in 2012, said he has up to eight headaches a day. Of the medicines available, he said, “I’ve tried them all, with varying levels of success.”
For the last 21/2 years, he’s been receiving infusions of the anesthetic drug ketamine at Jefferson. By far, he said, that has worked best, though he still has constant, “light” head pain. His doctor, Young, said he is collecting information about patients such as Hannah.
Bob Wold, a Chicago-area man who has had cluster headaches for 38 years, started another support group, Clusterbusters, in 2002. He said he has tried 70 medications in myriad combinations with little relief. For the last 15 years, he has used something else that largely keeps the headaches at bay: magic mushrooms, or, presumably their active ingredient, psilocybin. He said four to six doses of mushrooms a year have let him stop all other medications for the last decade. He still uses oxygen occasionally.
Wold became intrigued when a Scottish patient on a message board mentioned in 1998 that his headaches had gone away after he took LSD recreationally. LSD was hard to get in this country, but other patients began reporting that mushrooms, which are similar chemically, helped them, too. Most, he said, consume amounts well below a recreational dose.
Both LSD and psilocybin are considered illegal, schedule I drugs in the United States, meaning they have no accepted medical use and a “high potential for abuse.” State laws vary, but it is generally illegal to possess psilocybin mushrooms. However, Wold said, spores are readily available on the internet, and patients can grow their own. He was not aware of arrests.
Wold’s group has been pushing for high-quality science on mushrooms. Wold, who owns his own construction business and doesn’t have a college degree, was intimidated when he went to Harvard University to beg for research on psychedelics.
The result was a report in the scientific journal Neurology in 2006, based on a survey of 53 cluster-headache patients who had tried mushrooms or LSD on their own. Eighty-five percent of respondents who tried the drugs during attacks said the pain stopped. Fifty-two percent said psilocybin stopped a cluster of headaches. The authors point out that the online survey may have disproportionately attracted people who had gotten good results.
Because the placebo response is notoriously high in pain research, the results should be taken with a grain of salt, but they were a foot in the door.
An intriguing alternative
John Halpern, a Harvard psychiatrist who has studied hallucinogenic drugs and was involved in the Neurology survey, was intrigued enough to pursue further research. Before attempting to get approval to study an illegal substance, he looked at other compounds similar to LSD. He found one, 2-bromo-LSD, that was very much like LSD but did not cause hallucinations. He worked with some German doctors to test that drug, which has few side effects, on patients in Europe.
That very small study – just five patients – was also intriguing. Three doses were able to break a cycle or improve the frequency and intensity of attacks.
Halpern was so convinced that the drug could be useful – and better than psilocybin – that he started a company and began trying to attract pharmaceutical company funding to test it. He got nowhere.
“This can be potentially life-changing,” he said. “It just breaks my heart.”
He recently left Harvard to be medical director of a new addictions-treatment hospital.
Meanwhile, Wold said, a team at Yale University has decided to pick up the work on psilocybin. Yale declined to comment.
Several headache specialists said they couldn’t endorse the use of mushrooms but expressed sympathy with their patients and interest in their results.
“There’s starting to be more of a recognition that some of the naturally occurring substances that haven’t been considered up till now may have a risk/benefit ratio that’s as good or better than things we can prescribe,” Penn’s Detre said.
Several experts said the cluster-headache patients mostly do not seem interested in the recreational effects of the drugs. “I’ve met loads of these people, and they’re not people who have done drugs before,” said Joanna Kempner, a sociologist at Rutgers University who has studied migraine and cluster patients. “They take these drugs very much as medicine.”
Caution on psilocybin
Hannah said he tried mushrooms and the treatment made his headaches worse. He worries that psilocybin might harm patients with psychological problems and wants bigger, scientific studies before urging patients to try it.
Doctors at Jefferson and Penn Medicine said new treatments are in the works. Both systems are testing whether a monoclonal antibody known as LY2951742 (galcanezumab) can prevent both episodic and chronic cluster headaches. It targets the CGRP peptide, which is elevated in migraines and cluster headaches.
Jefferson’s headache center also tested the electroCore vagus nerve stimulator, an electrical device that patients held against the side of their necks during headaches. The vagus nerve runs from the brain stem into the chest and abdomen.
The trial found positive results for episodic, but not chronic, headache. The stimulator is already approved in Europe and Canada.
A current trial is testing the sphenopalatine ganglion (SPG) stimulator, also already in use in Europe, for people with chronic cluster headaches. A study from earlier this year found that 45 percent of the 33 chronic cluster-headache patients in the trial had a positive response to the ATI Neurostimulation System.
Hannah is hopeful that more pharmaceutical companies and device-makers will take an interest in cluster headaches. “There’s money to be made,” he said.
Original Source – Click Here
Great video on Microdosing Psychedelics (Magic Mushroom Psilocybin)
Study: Magic mushrooms are the safest drug
But they’re still illegal.
If you’re looking to play it safe when it comes to illicit substances, look no further than the humble shroom. It’s non-addictive, hard to overdose on, and you can grow it yourself. And, according to a massive report by the Global Drug Survey, it sends the fewest people to the emergency room of any drug on the market. Take that, meth.
Perhaps the most dangerous thing about psychedelic mushrooms is that they’re easily confused for the poisonous kind. There are over 100 varieties of psilocybin-producing shroomies, which is the chemical that makes you trip when you eat them. Some of them are bound to look like toxic varietals, especially if you’re in a hurry to get high. Just as you should never grocery shop while hungry, you should never go mushroom hunting while jonesing for a trip.
Instead, you should befriend a mycologist (a person who studies mushrooms) so that they can help you find the sort of shroom. Most people who don’t buy their mushrooms tend to pick them themselves rather than grow them, which is the riskier—albeit faster—option. The magic varieties grow on every continent, though if you happen to be somewhere subtropical and humid you’ll find more types. A mycologist friend is extra handy in places like Colombia, New Zealand, Norway, Mexico, Brazil, and Scotland, where the Global Drug Survey shows more than a third of shroom consumers pick their own. In Finland, Germany, the Netherlands, and Belgium, people grow far more than they pick.
It’s actually very easy to grow your own magic mushrooms, and it ensures that you’ll never accidentally poison yourself (as long as you keep an eye out for dangerous mushroom mold). Which is not to say that you should grow them, because possession of hallucinogenic mushrooms or sale of spores with the intent of growing psychedelic mushrooms is strictly illegal in the United States. We’re just saying that if you did grow them, it would be safer than trying to pick them in the wild.
Depending on your proximity to EDM venues versus hippie compounds, LSD might be far easier to come by than magic mushrooms. Five times more people need emergency treatment for LSD than they do for shrooms, though that still puts LSD below alcohol, amphetamines, and synthetic cannabis in terms of safety. Of the 10,000 people who reported taking magic mushrooms, only 17 went to the hospital versus 95 on LSD.
More people probably seek treatment because LSD comes in pill form, where you have no real idea of the dosage (or whether it’s spiked with something else, like rat poison) unless you test it yourself. And honestly, who’s testing it themselves? You’re gonna pop the pill, or maybe pop just half the pill if you’re being a little less foolhardy.
LSD also lasts longer and affects way more receptors in your brain than shrooms do. Psychedelic mushrooms only directly affect your serotonin receptors, whereas LSD affects serotonin, dopamine, and a whole host of other stimulating receptors in your brain. Shrooms may have some indirect effect on dopamine levels, but it’s minimal at best. The longer, potentially more intense results from LSD aren’t likely to do actual damage to your brain. But they are likely to give you a bad trip. And really, that’s the main danger with all psychedelics—if you’re anxious before you start or you begin to feel paranoid, the mind-altering impacts from the drugs only amplify those feelings. People who freak out on bad trips can be a danger to themselves and their friends, and that accounts for most of the related hospital visits. If you really overdid it on the pills, you might need medication to calm you down for a while.
Other than that, hallucinogens are pretty safe. They can reduce anxiety, ease the intense pain of cluster headaches, alleviate OCD symptoms, improve depression, and boost the psychological state of terminal cancer patients. A 2006 double-blind study sponsored by the U.S. government found that about 80 percent of people who took psilocybin reported that their well-being improved and remained that way for months after their psychedelic experience (the control group did not). Even over a year later, participants said that it was one of the most meaningful experience of their lives and that they continued to see benefits of it. Even if some of that is just them expecting to see long-lasting results from a psychedelic experience, it’s certainly compelling.
And you can’t even get addicted to them. Magic mushrooms give you short-term tolerance, which means taking more drugs to try to get a better trip won’t help you. Plus a high (pun intended) dose of mushrooms is more likely to make you paranoid than it is to make you feel the music better. If you can figure out the right dose for your body, you can get almost exactly the same high every time. Maybe that’s why the survey found that psychedelic users were among the most responsible drug users and took the most precautions. After all, reproducibility is the key to good science.
How Long Until We Can Grow Medicinal Magic Mushrooms: An Investigation
A wave of studies say psychedelics can treat depression, end-of-life anxiety, addiction and more. So we asked experts when Canadians will be able to grow medicinal shrooms at home.
It’s 2017, and legal weed is on the way—close enough that you might even have your first non-criminal session planned out. If you’re corny enough to imagine making history by sparking a joint on the steps of Parliament minutes after the paperwork is signed, it’s worth remembering you won’t be the first legal weed smoker in Canada.
Medical weed, and the right to grow it, has now been on the table for two decades, starting with an epileptic guy named Terrence Parker. After being charged with possession a bunch of times, Parker fought the government and won the right to be exempt from further growing and holding charges in 1997. An appeal court decided that exemption should apply to anyone growing for a medical purpose in 2000. Though regulations tried to outlaw homegrown medicinal bud again in 2013, that was struck down in court last year.
What we haven’t had in Canada (yet) is a legally-sanctioned medical shroom grower. With a wave of recent studies suggesting psychedelics are an effective treatment for depression, end-of-life anxiety, addiction and more, that prospect doesn’t seem as far fetched at it once did. As you can probably imagine, some fans are already looking at Canada’s path to medical weed, and applying the same arguments to magic mushrooms. Will that take another 20 years to grow your own? Or is the legal precedent already set?
Twenty-three-year-old Spencer Allison is on precisely this trip. He’s read much of the new research on psychedelic treatment for depression, as well as a few court decisions, and thinks it’s just a matter of time before he can grow his own medical mushies. Allison’s been bugging a bunch of bureaucrats at Health Canada for a new “section 56” exemption, just like Parker’s in ’97. So far, it’s not going so well.
Allison says he found the Parker case on Wikipedia, and went to the Ontario Court of Appeals site to get a summary of the arguments. “I went through that, hit Ctrl-F, and just started changing every mention of epilepsy to depression, and found anything that applied to marijuana also worked for LSD and other psychedelics.”
Allison thinks the very same argument will eventually force the government to let him legally grow at home. “I think it’s just a matter of when, more or less.” Given all the excitement (and caution) over psilocybin’s medicinal possibilities, I decided to call a few science and legal experts to find out if Allison’s optimism holds up to scrutiny.
When I called up Mark Haden of the Multidisciplinary Association for Psychedelic Studies, aka MAPS, he said weed and mushrooms are entirely different drugs, and their legalization will probably be super different, too. Haden recently put out a paper that laid out how he thinks psychedelics should be regulated in Canada, including a new agency of government-licensed trip sitters.
“The path to legalization of cannabis is completely different. The path to legalization of cannabis has been political,” he told VICE. According to Haden, because psychedelics don’t have the same widespread popularity that weed does, we’ll never see mushrooms on a ballot question in the states, or the right to micro-dose rolled into a major policy plank in Canada’s next election.
But that doesn’t necessarily mean legal shrooms is a long way off, says Haden. Because medicinal tripping is so niche, he says it is more likely to be handled like any other new treatment seeking government approval. “Basically it’s called drug discovery, and any pharmaceutical company who has ever produced a prescription drug is going through the stages we’re going through,” he told VICE.
MAPS is actually in a third stage of clinical trials for MDMA-assisted psychotherapy treatment for victims of trauma, something Haden says is on track to become a prescription by 2021. A second study into the effects of psychedelic mushrooms on depression is at about the same stage, with clinical trials showing promise.
“My understanding is they’re on the same timeline that we’re on,” Haden told VICE. “When we finish our phase three study, we submit our data to Health Canada… and they look at it and say ‘we approve.'”
If all goes well, Haden expects there will be separate certification for growing at home. Patients who get approval from their doctor would perhaps do a weekend training course, to get a basic understanding of setting, safety and dosage. But before we get there—he’s guessing a four to five year timeline—Haden anticipates there’ll be some resistance. For one, psychedelic treatment for depression would hurt the bottom line of any company in the anti-depressants market. But what pharmaceutical companies will do to protect those profits is still “up to speculation,” according to Haden.
Just like with weed, a court challenge could force a decision on the issue. John Conroy was part of the legal team that helped strike down Canadian regulations that banned personal weed growing for medical purposes, and he sees some parallels to the case for psilocybin.
The fact that psychedelic mushrooms grow in the wild makes for a similarly interesting case, according to Conroy. He recalls a decade-old controversy over what to do when mushrooms showed up in farmer’s fields. “I remember going to a meeting many years ago, when it was popular, and hearing people say ‘So what am I supposed to do if the stuff grows wild in my fields? Do I have to smack ’em over the head?'”
But Conway says despite the legal parallels, he hasn’t heard much interest in getting a challenge like that going. “To the best of my knowledge it would be similar to marijuana. You would need a doctor that’s supportive,” Conroy said, adding that there would probably need to be criminal charges brought against the mushroom grower. “Going into court, you could bring an Allard-type case forward.”
When asked about obstacles, Conway said getting doctors on board to prescribe could be the hardest part. Most of them aren’t into “whole plant” medicine, he said, and medical colleges have pushed back against marijuana policy reform.
But with weed setting the stage this year, both Haden and Conroy seemed to think mushrooms could follow a speedier path to home cultivation. Drawing comparison to other civil rights shifts, Haden sees an extended period of debate and protest leading up to several rapid changes in drug policy.
“When the balloon pops, it pops pretty darn quickly,” he said. ‘Cannabis was the first leaking of air out of the balloon.”
Cannabis related Research and other substances that help me
Psilocybin found in Magic Mushrooms give me the most relief. Here are links to the science behind these amazing substances.
Response of cluster headache to psilocybin and LSD. – PubMed
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on the effects of psilocybin and LSD on cluster headache may be warranted.
Psilocybin and LSD in the Treatment of Cluster Headache
THE THEORY AND PROTOCOLS
This treatment, commonly referred to as ‘busting’ is a way of using hallucinogenic tryptamines such as psilocybin to relieve cluster headache. Many cluster headache sufferers, affectionately called “Clusterheads,” find that small, sub-hallucinogenic doses of these tryptamines can end cluster headache cycles and prevent entire cycles from starting.
It may seem extreme to resort to hallucinogens, but a cluster headache is nothing if not extreme. It’s been called the worst headache, or pain of any kind, known to medicine. It is also called suicide headache, as suicide is known as a thankfully-rare symptom. Many clusterheads facing this beast call it just that: the Beast.
Many medications are effective to some degree. High-volume pure oxygen, or triptans such as Imitrex injections are commonly used to relieve individual attacks. There are many treatments to prevent attacks, including verapamil, lithium and steroids; these vary in effectiveness and severity of side effects.
Tryptamines may be more effective for preventive use, and if used carefully produce fewer side effects by far. For aborting attacks, they rival oxygen in safety and effectiveness.
Tryptamines have their dangers. Aside from being illegal in most countries, they are powerful drugs and must be respected. Pregnant women and people prone to mental illness should not use tryptamines. While it is not necessary to experience a psychedelic trip in order to treat cluster headache, a trip remains a possibility, and one should be prepared.
These pages are rundown of the protocols and procedures being developed for future research. These are not rules for treatment, rather a discussion of ideas and experiences from those using this method and the intention is to foster further research and development. There is much yet to learn and understand – and much to discuss with your physician – before attempting this treatment.
Index of pages: (all linked below)
warnings, the psilocybin mushroom, LSA seeds, playing well together, shutting the door, the dosing method, ways to take, coping, oxygen, the experience, keeping track, how well does this work, other tryptamines.
WARNING – TRYPTAMINES ARE NOT FOR EVERYONE
- Do not use tryptamines if you are pregnant, they can cause miscarriage.
- Do not use tryptamines if you suffer from or are prone to mental illness.
- Take tryptamines only in the proper mind set and physical setting.
- Tryptamines have physiological effects.
- Tryptamines are illegal.
- We are not doctors. This is not medical advice.
- Take no medication and use no treatment without consulting a physician.
- Obtain a through and accurate diagnosis from a knowledgeable doctor or neurologist before assuming you suffer from cluster headache.
For more detailed warnings see the WARNINGS page.
Information on this web site is for peer support purposes only. Information included should not replace necessary medical consultations with a qualified health professional to meet your individual health or medical needs, or those of your loved ones.
The information provided on this web site and on the ClusterBusters Message Board is with the understanding that ClusterBusters (or its host websites) is not engaged in rendering professional medical services or advice.
By accessing this web site and the ClusterBusters Message Board, you agree to hold ClusterBusters and its affiliates, its assignees, licensees, owners, officers, moderators, administrators, webmasters and directors harmless from any loss, claim or damage arising from your use of any of the information and ideas contained on the site, including following suggestions or advice posted on the message boards.
We, the Operators of this Website, provide it as a public service to our users.
If you have questions regarding these policies please contact us.
Psilocybin and lysergic acid amide (LSA) are the hallucinogens most used in this method. Both belong to the tryptamine family of chemicals. LSD is another tryptamine effective against clusters, and there may be others, including a relative of LSD that causes no hallucinogenic effects – research is ongoing.
There are natural sources for some tryptamines: psilocybin can be found in the psilocybe family of “magic mushrooms” or “shrooms.” The seeds of certain flowering vines contain LSA. Since most tryptamines are illegal, using natural sources is safer, more reliable and avoids involvement with criminal elements.
For more about psilocybin see THE PSILOCYBIN MUSHROOM
For more on LSA, see LSA – SEEDS OF THE VINE
For more on other useful tryptamines see OTHER TRYPTAMINES
THE INTERACTION PROBLEM
Unfortunately, many of the medications used to treat cluster headache tend to interfere with the effectiveness of the tryptamines. A period of “detoxification,” under a doctor’s supervision of course, is needed to clear these drugs from the system.
Imitrex and other triptans, steroids such as Prednisone, and many other medications can interfere. Some cluster medications can unpredictably increase the psychedelic effects of tryptamines. There are many medications where little is known, especially those taken for other conditions.
There are effective treatments to use during the “detox” period. Breathing high levels of oxygen through non-rebreather masks is very effective. Large amounts of coffee, or taurine energy drinks drank quickly are favorite emergency treatments. And there are the physical coping techniques: ice packs, hot showers, cold water, hard exercise, intense swearing and any number of strange and extreme things clusterheads do to battle the Beast.
THE DOSING METHOD
Clusterheads use tryptamine substances in a variety of ways. During a cycle, many take a small to moderate dose of psilocybin or LSA every five days or so, until the cycle stops. In some cases, only two or three doses are needed, others may find they must dose roughly once a week or every two weeks.
Better yet, Clusterheads have found they can take a few small doses before a cluster headache cycle is expected to start, and find the cycle never arrives, or is greatly reduced. Some have had success using even smaller doses to stop individual cluster attacks.
For more informations, see THE DOSING METHOD.
The idea here is to experience the maximum cluster relief with a minimum of psychoactive effects. A moderate dose of psilocybin might cause as much high as a couple of beers, though it is a different kind of high. Small doses can be effective even though the effects are slight to none. With LSA seeds, most people will experience little or no side effects at cluster treatment doses – some report drowsiness, some nothing at all. However, LSA can cause significant psychedelic experiences in some people.
While small doses are enough to treat clusters, tryptamines are powerful hallucinogens and must be used with caution. Those with a tendency toward mental illness should avoid tryptamines or any other hallucinogen. The plan is to minimize the high, but also to prepare for any psychedelic experiences that might come along. Every person is different, and every natural substance – mushroom or seed – may differ significantly in potency. See WARNINGS
There is promising research involving a tryptamine that does not cause significant psychoactive effects, and if it confirmed, could enable many more people to consider this method. To learn more, read HOW WELL DOES THIS WORK?.
For more on the experience of using tryptamines to treat clusters, see THE EXPERIENCE
The effect of tryptamines on clusters can seem like magic at first – surprisingly fast and complete. But it’s not magic, it’s neurochemistry, and it’s not over until the proverbial opera performance ends.
Everyone is different, but there often is an immediate sense of relief, followed within a few hours or a day or two, by the return of cluster attacks. These “slap-backs” can be abnormal attacks – shorter or longer than usual, or more painful or less painful than usual, and coming at odd times. There might be a few or several but these attacks then may begin to fade, at least for a while.
Symptoms may gradually return or continue at a low level, and a repeat dose is needed. For many, two or three doses can end a cycle. Some find they must repeat the dose every week or two, gradually stretching out the time between doses until the cycle ends.
Tryptamines don’t seem to work on some people. For others it is extraordinarily effective. One sufferer of chronic cluster headaches reported being pain-free for years after a single dose. Another reported no relief at all after several relatively strong doses. For more on the results of this treatment see SO HOW WELL DOES THIS WORK?: Works Well
The same treatments and coping methods used in the detox period can be used for these “slap-back” attacks and residual symptoms. Oxygen seems to be particularly effective when using the tryptamine treatment. For more on this, see COPING: BUSTER-FRIENDLY TREATMENTS.
Be sure to read the OXYGEN INFORMATION page. Oxygen is a lifesaver for many cluster headache sufferers.
Make no mistake, these substances are illegal, even when only used to treat cluster headaches.
We cannot and do not recommend buying drugs on the street – it’s illegal and dangerous. Drug dealers are hardly the most savory or trustworthy of individuals, and the drugs they sell might not be what they claim.
There are ways to obtain psilocybin and LSA seeds without dealing with a criminal element, but these other ways are also illegal. In fact, it might be more illegal (a felony) to grow your own mushrooms than to buy them from a drug dealer and possess them (often a misdemeanor). This is not how it should be, and the Clusterbusters hope for a day when drug laws are more rational.
Tryptamines are illegal.
Most all of them, most everywhere. Now understand – we are not lawyers, this is not legal advice, and the law can be complex and vary widely from place to place. When in doubt consult a licensed attorney familiar with the laws in your location.
Seeds containing LSA might be legal to buy, sell, grow and possess in some places. But not to eat. Eating RC, HBWR and Morning glory seeds is usually illegal. Even to treat cluster headaches.
Psilocybin mushrooms are illegal almost everywhere. They might be legal in the Netherlands, but that could change at any time. There may be countries where the government doesn’t care much about mushrooms being illegal, but you can’t count on that. In some parts of then US, you can have shrooms growing on your land, as long as you can reasonably show you didn’t know about it. But if you pick and eat them, that means you knew about it. In most US states (except Georgia and California), psilocybin mushroom spores can be possessed, but only for educational or scientific purposes. You can look at them with a microscope, but you’re not allowed to grow them into mushrooms. Eating spores doesn’t help – they contain no psilocybin.
LSD is illegal everywhere for anything, unless you have a research license. Which you don’t.
DMT concoctions like Ayahuasca are illegal everywhere unless you belong to certain religions in certain countries, which you don’t. And no, you can’t join these religions over the Internet.
The best thing to do is to assume all tryptamines are always illegal, and discretion is always wise.
For more about legal matters, click here: LEGAL.
In 2006, Dr. John Halpern and Dr. Andrew Sewell reported to the National Headache Foundation Research Summit on their case review study, later published in the journal Neurology. They reviewed reports from Clusterheads and found over 80 percent reported significant relief using tryptamines.
These results confirmed several hundred anecdotal reports of treating cluster headaches with tryptamines. A review of these reports shows about 67 percent of chronic cluster headache sufferers and about 75 percent of episodic sufferers report significant relief. These reports were mostly collected from Internet discussion groups and internet survey forms; they aren’t scientifically valid, but provide dramatic testimony from clusterheads finding relief. More formal research is in the works, see HOW WELL DOES THIS WORK?
We don’t know how this works. The current theory is one of SHUTTING THE DOOR. There is informed speculation on how such small amounts of substances can overcome such large headaches, but there is much to be learned. It’s serious neurology, of course. Some ideas seem to center on the way tryptamines constrict blood vessels; others involve the way the indole-ring molecule of the tryptamines fits into seratonin receptors. Particularly interesting is the way small, infrequent doses can have long-lasting effects and seem to work best if taken at intervals of several days.
Of course, it is not magic even if it seems like it, and serious scientific research into the mechanism of both cluster headache and tryptamine effects on the brain would go a long way toward eliminating much massive pain.
DON’T STOP NOW
Don’t stop reading now. Read everything here. Please don’t use tryptamines without researching and studying the matter thoroughly and consulting your physician.
READ THIS FIRST!
TRYPTAMINES ARE NOT FOR EVERYONE
Do not use tryptamines if you are pregnant; they can cause miscarriage.
Do not use tryptamines if you suffer from or are prone to mental illness.
Tryptamines may interact with other medications.
Tryptamines have physiological effects.
People diagnosed in the past or present with a psychotic disorder, or people with biological parents or siblings diagnosed with a psychotic disorder should not take tryptamines, including LSD, psilocybin, DMT and LSA. Psychotic disorders include schizophrenia, delusional disorder, affective (mood-related) psychosis and others. Tryptamines may exacerbate symptoms of psychosis or trigger psychosis in people who were psychotic in the past, or with immediate family members who were or are psychotic.
Taking tryptamines during or immediately after a period of emotional upheaval, such as a relationship breakup the death of a loved one, may intensify negative emotions, even to a proportion that feels “out of control.”
Tryptamines should only be taken when one feels confident and secure in his or her ability to handle a psychedelic experience and is confident in the stability of one’s mind set.
Tryptamines should be taken only in a place where one feels secure and with people they can trust.
Tryptamines and some of the chemicals found in natural substances containing tryptamines can cause miscarriage. Do not take tryptamines if you are pregnant or think you might be pregnant.
Use of some tryptamines is known to increase heart rate and blood pressure, so consult with your doctor if you suffer any conditions that would be negatively affected by this.
Reynaud’s syndrome (cold-triggered reduction or loss of circulation in fingers and toes) will be made worse by taking a vasoconstrictor, and tryptamines are vasoconstrictors.
People taking lithium, whether for preventing cluster headaches or for some other reason, should not use tryptamines. Anecdotal reports suggest lithium can greatly increase the psychoactive effects of tryptamines and that it can produce very unpleasant feelings, or even symptoms similar to epileptic seizures.
Tricyclic antidepressants, such as Trofanil (imipramine), Anafranil (clomipramine) and others, and MAOIs taken along with tryptamines, may greatly intensify the psychoactive effects.
People with serious liver problems should avoid psilocybin mushrooms as some might have compounds that could affect the liver.
TRYPTAMINES ARE ILLEGAL
Most all of them, most everywhere. Now understand – we are not lawyers, this is not legal advice, and the law can be complex and vary widely from place to place. When in doubt consult a licensed attorney familiar with the laws in your location.
Seeds containing LSA might be legal to buy, sell, grow and possess in some places. But not to eat. Eating RC, HBWR and Morning glory seeds is usually illegal. Even to treat cluster headaches.
Psilocybin mushrooms are illegal almost everywhere. They might be legal in the Netherlands, but that could change at any time. There may be countries where the government doesn’t care much about mushrooms being illegal, but you can’t count on that. In some parts of then US, you can have shrooms growing on your land, as long as you can reasonably show you didn’t know about it. But if you pick and eat them, that means you knew about it.
In most US states (except Georgia and California), psilocybin mushroom spores can be possessed, but only for educational or scientific purposes. You can look at them with a microscope, but you’re not allowed to grow them into mushrooms. Eating spores doesn’t help – they contain no psilocybin.
LSD is illegal everywhere for anything, unless you have a research license. Which you don’t. DMT concoctions like Ayahuasca are illegal everywhere unless you belong to certain religions in certain countries, which you don’t. And no, you can’t join these religions over the Internet.
The best thing to do is to assume all tryptamines are always illegal, and discretion is always wise.